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The increasing frequency and complexity of neonatal care are key 
contributors to rising medical costs. Over the past twenty years, neonatal 
delivery rates have been increasing and infant mortality rates are improving. 
Neonatal care has become very expensive with few applicable clinical guidelines 
for care. 
ParadigmHealth has developed an integrated, care management structure 
termed Systematic Care Management© (SCM). The premise is that by 
promoting the most expert and efficient neonatal care, significant reductions in 
morbidity will occur, reducing the need for and reduced cost of NICU and 
subsequent care. The aim of the study was to determine whether the SCM 
process is associated with reductions in neonatal average length of hospital stay. 
While inconclusive, the results of this study indicate that the application of 
this system is associated with reductions in NICU average lengths of stay for 
severity-match neonates. Further experience and analysis is needed to confirm 
these findings. 
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I. Introduction 
High-risk births, which are increasing in frequency and complexity, are 
among the leading conditions contributing to the rise in the nation's health care 
costs (Lantos, 2001). National statistics reveal that the delivery rates of preterm 
and low birthweight (LBW) infants have been slowly increasing over the past 20 
years. These infants comprise the major percentage of neonatal intensive care 
unit (NICU) admissions (Friedman, Devers, Steiner, & Fox, 2002). 
These increasing rates of high-risk births would have been expected to 
lead to an increase in neonatal mortality rates. However, continuing 
improvements in neonatal intensive care have served to consistently improve 
mortality rates across all birth weights (Friedman et aI., 2002). Over the past 
twenty years, as the field of neonatal medicine has made profound advances in 
knowledge and technology, infant mortality has significantly declined in all 
developed nations (Organization for Economic Co-operation and Development, 
1999). 
It has been reported that, as early as 1990, the net cost (excess of cost 
over that of normal birth) of both premature and problem-related births had 
reached approximately $5.6 billion per year - an estimated 30/0 of aggregate after 
tax corporate profits (Thompson, Goodman, & Little, 2002). Advances in 
technologic capabilities are not only making the care of such high-risk births 
more expensive, but confound efforts to produce generally applicable guidelines 
for care (Lantos, 2001 ). 
2 
The United States has the largest neonatal workforce and hospital 
capacity in the world (Pasko & Seidman, 1999). Yet studies suggest that the 
relative emphasis toward neonatal intensive care resources is not associated 
with better birthweight-specific survival (Goodman & Little, 1998; Fisher & Welch, 
1999; Rosenblatt, 1989). In fact, the oversupply of neonatologists and NICUs 
may paradoxically lead to less effective care, as the number of severely ill 
newborns per neonatologist and per NICU decreases (Phibbs, Bronstein, Buxton, 
& Phibbs, 1996). Thompson et al. (2002) suggest that perhaps there is a 
threshold where additional neonatal resources yield little measurable benefit. 
A Systematic Care Management Method 
ParadigmHealth Corporation (ParadigmHealth) has developed through a 
modified Delphi technique, an integrated management structure to address these 
complex neonatal management issues. This process of care is termed 
Systematic Care Management (SCM). Preliminary descriptions of this process 
have been published (Carter, Koffler, & McLean, 1999; Cope, Bryant, & 
Sundance, 2001; Cope and O'Lear, 1993). The premise of this system is that by 
reliably promoting the most expert and most efficient care for these very complex 
infants, significant reductions in morbidity will occur, and that these will translate 




The objective of this study is to validate the effectiveness of 
ParadigmHealth's systematic care management (SCM) model in reducing the 
average length of stay for infants in an NICU. The SCM model encompasses a 
process specifically designed to address the challenge of extremely complex 
medical problems (Cope & Sundance, 1995). SCM represents 
comprehensiveness, coordinated communication, medical service integration, 
and supplements the basic principles of traditional case management with fiscal 
accountability and the development and use of evidence-based, data-driven 
clinical pathways (Cope & Sundance, 1995). It has found acceptance and utility 
by providers, patients, and payers in a wide range of clinical conditions, including 
high-risk neonates (Cope, Bryant et aI., 2001). 
Background and Need 
Enormous resources are invested in health care in the United States. In 
1998, national health care expenditures were greater than $1.1 trillion (Levit et 
aI., 2000). This 14.10/0 of the national gross domestic product is demonstrated in 
the average of $5,035 per person that Americans spend on health care each 
year, higher than in any other country in the world (Mcintosh, 2002). The 
excessive growth in the costs and complexity of health care in the United States 
is expected to continue, with health care expenditures projected to reach $2.3 
trillion dollars (15.5% to 16.60/0 of GDP) by 2008 (Longest, 2001). These 
increases are occurring concurrently with significant breakdowns in the 
organization and delivery of health care, resulting in a health care delivery 
system that lacks appropriate clinical and administrative information systems 
(Richardson, 2001). 
4 
The American public has placed the state of health care today as a 
primary domestic concern (Donelan, Blendon, Schoen, Davis, & Binns, 1999). 
Few are happy with the system as it currently operates. The basic issues 
underlying efforts to improve the U.S. health care system are concerned mainly 
with reducing costs, increasing access to health care (especially for the 
uninsured or underinsured), and further improving and maintaining quality health 
care (Geyman, 2002; Longest, 2001; Sultz & Young, 1997). In recent years, 
improving the quality of U.S. health care has become a national focus with the 
Institute of Medicine releasing a sUbstantive report outlining a twelve-point 
process for such improvement (Kahn, Corrigan & Donaldson, 2001). The central 
theme of this report, Crossing the Quality Chasm: A New Health System for the 
21 st Century, is the belief that there must be a fundamental restructuring of our 
healthcare delivery system with a focus on evidence-based medicine and 
outcomes (Kohn et aI., 2001; Geyman, 2002). Yet reliable and timely information 
about health care and its outcomes is lacking for even the most basic of health 
conditions (Mcintosh, 2002). 
Managed care has introduced multiple financial and management 
strategies with the intent of restraining costs while maintaining appropriate quality 
of care. These include the following: price controls (limiting reimbursement for 
5 
individuals or aggregate services}, diagnosis related group reimbursement or 
"DRGs" (provider reimbursement based upon a specific diagnostic code), 
preferred provider organizations or "PPOs" (reduced rates from contracted 
providers in return for an expected increase in volume), capitation (provider 
reimbursement based upon a "per member per month" rate of payment 
regardless of services provided), peer review (physician/medical expert review of 
services provided), utilization review or "UR" (external review of need for ongoing 
prescribed services), and case management (primarily a nurse-oriented 
utilization review or cost containment) (Miller & Luft, 1997). While these 
strategies have had some positive effect, both consumers and providers of care 
consistently view them as heavy-handed, arbitrary, and intrusive (Cope, Bryant et 
aI., 2001; Mcintosh, 2002). 
The short-term savings (reflected in reduced premiums for the next annual 
insurance contract cycle) have become the primary determinant of success for 
health plans. It has been documented that neither the purchasers nor the 
providers of health care have developed methods of financing or service delivery 
which successfully lead to appropriate and affordable high quality care for 
patients with complex medical conditions (Cope, Bryant et aI., 2001; Sandy & 
Gibson, 1996; Sutton & Dejong, 1998; Tanenbaum & Hurely, 1995). In addition, 
despite numerous attempts to manage health care expenditures, costs continue 
to rise at double digit rates (Ginsberg, 1999; Smith, Freeland, Heffler, & 
McKusick, 1998), and morbidity continues to escalate secondary to unnecessary, 
inadequate, inexpert, or inefficient care (Gray & Fields, 1989; Jenkins, 2000; 
Mechanic, 1997; Schwartz, 1998). 
Purpose of the Study 
This study will be the first analysis of ParadigmHealth's neonatal 
management system, referred to as Systematic Care Management. The study 
will encompass three years of ParadigmHealth's experience with this population 
of high-risk births (1998, 1999, and 2000). Its purpose is to demonstrate that 
this process of management is associated with significant reductions in the 
average length of stay (ALaS) of complex, high-risk neonates during their initial 
NICU hospitalization. 
Significance of the Study 
6 
Over the past few decades, neonatal intensive care has confronted, 
clashed with, and in many ways adapted our collective medical consciousness. 
Through advances in technology and science, physicians have developed 
methods to save the lives of an entire population of infants who once were 
thought too small or fragile to survive (Grumbach, 2002; Lantos, 2001). Neonatal 
intensive care has changed the way we think about what infants demand from 
our society and about what we, collectively, owe to them. It has changed the 
way physicians, hospitals, and academic medical centers conceptualize their 
missions. In many cases, neonatal intensive care has become the centerpiece of 
tertiary care pediatrics (Friedman, Devers, Steiner, & Fox, 2002; Lantos, 2001). 
7 
NICUs have become not just the focus of pediatric scholarly work but also the 
economic lifeblood of academic medical centers (Gleid & Gnanasekaran, 1996). 
Nationally, about 53,000 infants are born with a birthweight of less than three 
pounds. At today's survival rates, these infants will account for 2.1 million 
hospital bed days. Just ten years ago survival rates were 30-50% lower (and 
would have accounted for only 1.6 million hospital bed days). As a result, NICUs 
have become the economic engine that keeps children's hospitals running 
(Friedman et aI., 2002; Goodman, Fisher et aI., 2002; Lantos, 2001). 
Buoyed with this positive affirmation of improved mortality, the 
practitioners of neonatal intensive care have been somewhat sheltered from the 
cost-containment methods of managed care (Friedman et aI., 2002; Gerber, 
Dobrez, & Bidetti, 2001). It is believed, however, that the delivery of neonatal 
care, as with areas of adult intensive care, remains below obtainable levels of 
appropriate lengths of stay, cost, and customer value. NICUs are economically 
successful because they are medically successful. Given the costly nature of 
care for these critically ill infants, payer organizations continue to search for ways 
to manage these costs more effectively (Ginsburg & Ostow, 1997). This study 
will seek evidence that SCM is an effective method for managing these costs by 
reducing the mean length of stay for infants admitted to the NICU. 
In an era of cost containment and accountability for quality of care, any 
connection between experience and patient outcome has far-reaching 
implications for patients, payers, and governmental agencies (Brinkmeyer, 
Brinkmeyer, Wennberg, & Young, 2000; Freund, Rossiter, & Fox, 1989; Jameson 
& Wehr, 1993; Jencks, 1997; Musci, Esslinger, & Kornhauser, 2001). Despite 
compelling evidence of the value of highly specialized neonatal intensive care 
units, questions remain about the proliferation of these units and the clinical 
processes that determine length of stay (Chenoweth, 2001; CIGNA HealthCare, 
1992; Grumbach, 2002). This study will examine whether SCM is also effective 
in reducing the variability that exists (Musci et aI., 2001) in NICU lengths of stay. 
Specific Aims 
This study had two (2) specific goals: 
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1. To determine whether the SCM process of management is associated 
with significant reductions in the average length of stay (ALOS) of high-
risk neonates during their initial NICU hospitalization. 
2. To determine whether SCM is effective in reducing the range of NICU 
lengths of stay (LOS). 
Research Hypotheses 
The study had two (2) primary hypotheses: 
H1: There is evidence that ParadigmHealth's Systematic Care 
Management (SCM) process results in a reduction in NICU average 
length of stay (ALOS). 
H2: There is evidence that the SCM process reduces the range of 
patient length of stay) in the high-risk neonate (NICU) population. 
The balance of this manuscript will present a review of the literature in 
chapter two. A detailed discussion of the project's methodology is found in 
chapter three. Chapter four contains the results of the analysis process. A 
discussion of the findings, conclusions, applications, limitations and lessons 
observed during the project are presented in chapter five. 
9 
II. Literature Review 
Introduction 
The US health care system has a long-standing reputation as being one of 
the most advanced and sophisticated health care systems in the world 
(Browning, 1992; Sultz & Young, 1997). The desire of patients and physicians 
for increasingly more advanced (and costly) health care, coupled with the 
willingness of third-party payers to meet the costs of providing it, has generated 
ample encouragement for speedy technological advancement (Weisbrod, 1991). 
These advances in biomedical science have largely propelled the evolution of the 
nation's health care system as well as the explosion in the costs of providing 
such sophisticated care. 
The costs of providing health care in the United States have increased 
dramatically, from $27.1 billion in 1960 to $884.2 billion in 1993 (Ayres, 1996; 
Sultz & Young, 1997). Longest (2001) found that Americans spent more than $1 
trillion in pursuit of health in 1997 and expects this total to rise to $1.5 trillion this 
year. Today, the United States spends 40% more per capita on health care than 
any other Western industrialized nation (Mcintosh, 2002; Guyer, Freedman, 
Strobino, & Sondik, 2000). 
11 
Our health care industry continues to be one of the largest, most diverse, 
and fastest growing industries in the country (Geyman, 2002). It comprised one 
seventh of the US economy in 1998 (Mcintosh, 2002). The national health care 
expenditures have risen faster than most other components of the US economy 
(Browning, 1992). This growth in the costs and complexity of health care in the 
United States is expected to continue with health care expenditures projected to 
reach $2.3 trillion (15.50/0 to 16.60/0 of GDP) by 2008 and $2.8 trillion (17% of 
GDP) by 2011 (eMS, 2002). These increases are occurring concurrently with 
significant breakdowns in the organization and delivery of health care, resulting in 
a health care delivery system that lacks appropriate clinical and administrative 
information systems (Richardson, 2001). 
The Premise of Managed Care 
Managed care describes a collection of healthplan activities designed to 
reduce the high levels of utilization and spending that accompanied unfettered 
fee-for-service medicine (Baker & Phibbs, 2002; Zwanziger & Melnick, 1996). 
The activities that fall under the rubric of managed care can be loosely placed in 
three groups. First, managed care plans attempt to alter financial incentives. 
Second, managed care plans often assert control over treatment decisions. 
Third, managed care plans often search for a set of physicians and hospitals with 
whom they desire to contract, negotiate with these providers, and then restrict 
their members to use the chosen providers (Zwanziger & Melnick, 1996). The 
belief on the part of the plans appears often to be that fee-for-service medicine 
12 
was characterized by excessive use of expensive tests and procedures, and they 
have frequently focused their attention on curbing the use of these services and 
reducing the amount they pay for them (Miller and Luft, 1997). 
An effective managed care system is one that has processes in place to 
evaluate patients' short-term and long-term needs and apply the appropriate 
model of care for each subgroup of its population (Zwanziger & Melnick, 1996). 
It is particularly important for a managed care system to be set up to plan 
carefully for the health care requirements of persons with catastrophic injuries or 
conditions, given the inevitably high cost of their care and their need for ancillary 
support services and long-term maintenance. However, our society's 
understanding of how well managed care has succeeded in planning and 
delivering the care of persons with catastrophic injuries and conditions requiring 
long-term oversight is extremely limited. For persons with special health care 
needs requiring long-term services, there is virtually no research evaluating the 
impact of managed care on long-term health (Applebaum & Mayberry, 1996; 
Berkowitz & Halfon, 1992). 
The published literature on managed care gives a mixed impression of its 
effectiveness overall in managing health care costs, improving access and 
quality of services and establishing equitable priorities for allocating health care 
resources (Freund et aI., 1989). On the plus side, cost management is facilitated 
by managed care's use of utilization controls (England & Muchnick-Baku, 1997) 
and provider reimbursement methodologies that offer incentives for health care 
providers to conserve resources. Managed care has been shown to provide 
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increased access to ancillary services, more extensive coverage of home health 
care and outpatient mental health services and more of a focus on case 
management compared with fee-far-service arrangements (Fox, Wicks, & 
Newacheck, 1993). 
Managed care organizations, while providing increased access to certain 
services, may place limits on the quantity or duration of services (Geyman, 
2002). The traditional managed care approach to cost containment emphasizes 
administrative procedures such as utilization review and pre-certification. The 
evidence indicates that managed care can increase service efficiency, reduce 
utilization of emergency rooms and inpatient services, decrease out-of-pocket 
costs, all with little effect on quality of care overall for the enrolled population 
compared with fee-far-service plans (Perrin, Newacheck & Pless, 1993). 
However, a number of authors have argued that such administrative cost-
constraining measures do have a deleterious effect on health status and 
outcomes and turn out to be secondarily cost-increasing as a result (Jameson & 
Wehr, 1993; Nelson, Brown, Gold, Ciemnecki, & Docteur, 1997). 
Before the advent of managed care, health insurers typically paid health 
care providers using fee-far-service reimbursement, exercising little oversight of 
treatment decisions made by patients and their physicians (Silver, 1997; Spitz, 
1987). Over the past fifteen years, multiple financial and management strategies 
have been developed with the intent of restraining costs while maintaining 
appropriate quality of care (Altemeir, 1995). Examples include price controls 
(limiting reimbursement for individuals or aggregate services), diagnosis-related 
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group reimbursement or DRGs (provider reimbursement based upon a specific 
diagnostic code), preferred provider organizations or PPOs (reduced rates from 
contracted providers in return for an expected increase in volume), capitation 
(provider reimbursement based upon a "per member per month" rate of payment 
regardless of services provided) (Zwanziger & Melnick, 1996), peer review 
(physician/medical expert review of services provided), utilization review or UR 
(external review of need for ongoing prescribed services), and case management 
(primarily a nurse UR cost containment function with the nurse, at times, not 
having insufficient expertise or power to significantly influence the care process) 
(Cope, Bryant, et aI., 2001; Horn, Sharkey, Tracy, et aI., 1996). 
While these strategies have had some positive effect, the previously 
mentioned methodologies are consistently viewed by both consumers and 
providers of care as heavy-handed, arbitrary, and intrusive, such that short-term 
savings (reflected in reduced premiums for the next annual insurance contract 
cycle) have become the primary determinant of success for health plans (Mark & 
Mueller, 1996). This should not come as a surprise since, dating back to 1912, 
five major attempts to reform the U.S. health care system have all failed 
(Mcintosh, 2002). 
Populations with special needs. There is evidence that managed care 
organizations particularly tend to under-serve certain subsets of patients. 
Vulnerable populations, such as the elderly, non-elderly disabled, persons with 
functional impairments, and persons with debilitating conditions, have had 
documented difficulties obtaining access to necessary services under managed 
care plans (Miller & Luft 1997; Nelson et aI., 1996; Petrou, Sach, & Davidson, 
2001). Plans may limit or deny coverage if they determine that a service is not 
medically necessary, experimental or investigative (Rosenblatt, 1989; Sandy & 
Gibson, 1996). 
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Some health maintenance organizations may be reluctant to pay for 
intensive early intervention or the kinds of cross disciplinary or specialty care that 
persons with chronic conditions require (Altemeir, 1995). There is a concern 
among some managed care organizations that if they do incorporate a broad 
continuum of services in their plan, they may attract a disproportionate share of 
persons with special health care needs (Altermeir, 1995). The tendency of 
managed care organizations to under-serve or even avoid enrollment of high-
cost populations who require disproportionately more services than the general 
population is a process known as adverse selection (Horn, Sharkey, Tracy et aI., 
1996; Luft & Miller 1988). 
In particular, it has been documented that neither the purchasers nor the 
providers of health care have developed methods of financial or service delivery 
managernent which successfully lead to appropriate and affordable high quality 
care for patients with complex chronic or disabling conditions. These conditions 
include catastrophic injuries or medical events such as acquired brain injuries, 
spinal cord injuries, severe multiple trauma, severe burns, and significantly 
premature infants (Cope, Bryant et aI., 2001; Sandy & Gibson, 1996; Sutton & 
Dejong, 1998; Tanenbaum & Hurely, 1996). In addition, despite many of these 
management attempts, costs continue to rise at double digit rates (Ginsburg, 
1999), and morbidity continues to escalate secondary to unnecessary, 
inadequate, inexpert, or inefficient care (Gray & Fields, 1989; Horn, Sharkey, 
Tracy et aI., 1996; Jenkins, 2000; Mechanic, 1997; Schwartz, 1998). 
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Caring for high-cost populations. High-cost populations, although they 
represent a minority of patients in today's health care environment, incur a 
disproportionate share of health care expenditures (Hobar, Badger, Lewit, 
Rogowski, & Shiono, 1997; Lessaris, Annibale, Southgate, Hulsey, & Ohning, 
2002). Such populations tend to require a complex set of care resources, 
extending across the full continuum of care and over a long-term time horizon. 
Today's health care organizations are particularly challenged to achieve their 
fundamental objectives for those sectors of the population that incur the highest 
costs (Thompson et aI., 2002). Such patients include those with catastrophic 
injuries, the severely chronically ill, those in the last year of life, and those born 
prematurely with very low birth weights (neonate). Many of these vulnerable 
groups are excluded from or inadequately integrated into managed care delivery 
systems, and their care historically has been fragmented and poorly coordinated 
(Lewit, Baker, Corman, & Shino, 1995; Miller & Luff, 1997). 
In view of the mixed evidence on managed care, it is not surprising that 
there is a growing concern in the policy community about maintaining access to 
appropriate care while controlling costs for critically ill populations (Sandy & 
Gibson, 1996; Stolz & McCormick, 1998). Rather than stirring up a backlash 
against managed care, however, a more productive response is to develop a 
philosophy and strategy of care management that supports and improves the 
effectiveness of managed care (Scott, 2000; Silver, 1997; Tanenbaum, 1994). 
Neonatal Intensive Care 
Currently, one of every nine births in the U.S. results in an admission to 
neonatal intensive care (Guyer et aI., 2000). Of the 3.8 million births in the U.S. 
annually almost 400,000 infants are treated in NICU, at a cost of over $9 billion 
nationally (Musci et aI., 2001) and at an average individual cost of more than 
$250,000 (Stolz & McCormick, 1998). 
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Since 1990, the United States has seen a 32% decrease in infant 
mortality, from 10.2 to 6.9 deaths per 1,000 live births (UnitedHealth Foundation, 
2002). Even with these improvements, the United States ranks 27th among 
developed countries in its infant mortality rate, just above Hungary and Slovenia 
(Eberhardt, Ingram, & Makuc, 2001). While recent advances in the technology 
and care delivery have improved the long and short-term outcomes of this 
population (Fawke & Mcintyre, 2002), the neonatal period continues to have the 
highest death rate in childhood (Guyer et aI., 2000). 
The intensity of caring for this complex patient population has been 
accompanied by concerns about cost effectiveness of high technology NICU 
environments (Friedman et aI., 2002; Lorenz & Jetton, 2001). In addition, 
concerns over racial and economic disparities in care have been documented 
(Demissie et aI., 2001; Gleid & Gnanasekaran, 1996; Rowland, Hogue, & 
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Vasquez, 2002). Others have questioned the eventual quality of life (Meadow, 
Frain et aI., 2002; Schwartz, 1996) and potential long-term health consequences 
for NICU survivors (Lewit et aI., 1995; Petrou et aI., 2001; Siomin, Patel, 
Ruttimann, & Pollack, 2000). 
The neonatal intensive care unit defined. Medical care for low birthweight 
infants is provided in neonatal intensive care units (NICUs) in hospitals with 
obstetric services or in children's hospitals. According to the American Academy 
of Pediatrics (1977) services in NICUs include constant nursing and continuous 
cardiopulmonary and other support for severely ill infants as well as other 
specialty services and technology. Generally, this care is provided by 
pediatricians with advanced training in neonatology, specialized nurses, and 
other specialized staff. Any given NICU contains a range of equipment and 
service capabilities that collectively represent the NICU technology (Baker & 
Phibbs, 2002). Not all birth hospitals have NICUs; infants who are born outside 
of NICU hospitals and who need such services are usually transferred to the 
nearest NICU facility (Bode, O'Shea, Metzguer, & Stiles, 2001; Chang & Klitzner, 
2002; McCormick & Richardson, 1995). 
The classification of neonatal intensive care units. Perinatal health care 
systems have evolved to deliver infants of pregnant women in health care 
facilities that range from level I (without neonatal intensive care units or high-risk 
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obstetric and pediatric staff) to level III (fully equipped, tertiary NICU facilities). 
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Between these two extremes are the level II units, often referred to as mid-level 
or "community" NICUs (Goodman, Fisher et aI., 2001). These units provide 
some of the advanced services of a level III, but not all. These mid-level units 
typically do not have the staff and equipment for treating rare and very serious 
cases or the staff and equipment to support complex neonatal surgeries (Baker & 
Phibbs, 2002; McCormick, Shapiro, & Starfield, 1985). 
Hospitals that host planned deliveries are equipped with a well-baby 
nursery, containing basic equipment for the care of healthy newborns and those 
with minor medical problems. Hospitals that offer only this level of service have 
no NICU and their infant care units are classed as level I nurseries (Cifuentes et 
aI., 2002). Infants delivered in a level III hospital have access to state-of-the-art 
medical care that both increases their survival chances and reduces risk of long-
term developmental and physical problems. Often referred to as regional or 
tertiary NICUs, these units provide a full range of specialized neonatal care for 
the most seriously ill newborns, including long-term mechanical ventilation, 
subspecialty consultants, and surgeries (Hein & Lofgren, 1999; Howell, 
Richardson, Ginsburg, & Foot, 2002). 
Although they are expensive, NICUs can have a powerful impact on the 
prognosis for high-risk infants, substantially lowering mortality rates for severely 
ill newborns and improving non-mortality outcomes for other sick infants 
(Williams & Chen, 1982). Research has shown that infants who are cared for in 
NICUs have better rates of survival than those who are not, after infant size and 
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gestation are controlled for (Howell et aI., 2002; Richardson, Gray, Gartman, 
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Purlsey, & McCormick, 1998). Another body of research has generally shown 
that infants born in higher-volume NICUs have better survival than those born in 
lower-volume facilities (Mayfield, Rosenblatt, Baldwin, Chu, & Logerfo, 1995; 
Phibbs, Bronstein et aI., 1998; Rosenthall, Harper, Quinn, & Cooper, 1997; 
Sanderson, Sappenfield, Jespersen, Liu, & Baker, 2000; Sankaran et aI., 2002). 
Relationship between length of stay and NICU costs. For some time 
researchers and practitioners have noted that there appears to be a complex, 
non-linear, inverse and temporal relationship between a neonatal intensive care 
patient's day of life and the quantity of hospital resources required to provide 
their care (Doyle, Murton, & Kitchen, 1988; Kaufman & Shepard, 1982). There 
are many causes for this phenomenon. In studies of costs in NICU, researchers 
have found that there is significant variability in cost of care among neonates in 
NICU (Lorenz & Jetton, 2001). These studies have attributed this variability to 
improved access and use of advanced technologies extending survival and 
length of stay (Behnke, Eyler, Conlon, Casanova, & Woods, 1997; Khoshnood et 
aI., 1996) rather than to individual practitioner (Perlstein, Atherton, Donovan, 
Richardson, & Kotagal, 1997; Schulman, Lucchese, & Sullivan, 1995) or 
organizational practices (Rogowski, Horbar et aI., 2001). In addition to length of 
stay, important indicators to the ultimate costs of NICU care were the presence of 
mechanical ventilation, parenteral nutrition, and advanced technology (Tyson & 
KennedYJ/2002). It should be noted that researchers have demonstrated that 
over 80% of the dollars spent in NICU will be spent on infants who ultimately 
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survive, compared to adult ICUs where less than 50% of all dollars will be spent 
on survivors (Meadow, Kim et aI., 2002; Mehta et aI., 2000). 
Since the later 1990's, the use of clinical practice protocols and guidelines 
as the standards for case management in neonatal care has provided an 
opportunity to study the effect of systematic care protocols in reducing the 
variability in NICU settings (Merritt, Palmer, Bergman, & Shiono, 1997). Several 
of these studies indicate that the use of clinical practice guidelines can directly 
affect newborn and NICU length of stay (Jones, 1994; Neidig, Megel, & Koehler, 
1992; Turley, Tyndall, & Rage, 1994), resulting in improved costs of care. The 
use of triage protocols in NICU contributed to reducing cost and length of stay by 
affecting not only the severity of illness but also acknowledging non-medical 
markers of resource consumption and unit structure (Zupancic & Richardson, 
1998). 
In the mid-1990's assessment of neonatal intensive care led to the 
development of economic models for determining cost of care and length of stay 
using financial and clinical data from the neonatal care experience (McCormick & 
Richardson, 1998; Phibbs, Phibbs, Pomerance, & Williams, 1986; Thomas & 
Ashcraft, 1991). The publication of these models ultimately resulted in the 
implementation of the APR-DRG system to both assist in differentiating risk in 
neonatal care and more fairly adjust for the complexity and variability of the 
neonatal care experience. 
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The Evolution of Evidence-Based Medicine 
The practice of medicine has long been recognized as a subtle mixture of 
art and science. This tenuous blend of "head and heart" has historically sparred 
debate as to the most correct approach in delivering patient care. Until recently, 
few tools have existed to identify superior treatment methods in medicine. As 
new tools and techniques have been developed to help practitioners better 
understand the optimal treatment of patients, medicine has begun a notable 
move toward an exact science (Sackett, Richardson, Rosenberg, & Haynes, 
1997). The past decade has shown tremendous and exciting growth in the 
development of this science, known today as evidence-based medicine (EBM) 
(Eisenberg, 1999). 
Over the past five years, EBM has clearly advanced medical knowledge. 
While many in the health care community have welcomed this move forward, 
some foresee potential erosion of individual professional autonomy and the loss 
of the art of medicine (Roscoff, 2001). Clinicians who have historically enjoyed 
wide latitude to exercise personal discretion in choosing treatments for their 
patients now may feel increasing pressure to conform to established norms of 
patient care (Hirshfield, 1991) as more becomes known about the "most correct" 
way to treat a particular medical condition (Tanenbaum, 1994). 
In an environment supportive of EBM, a clinician might more readily be 
held accountable for a poor patient outcome if that outcome can be attributed to 
deviation from an EBM-prescribed treatment approach (Hyams, Shapiro, & 
Brennan, 1996). As a result, EBM is seen by some medical professionals as 
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packing a one-two punch: erosion of autonomy in a treatment choice 
accompanied by greater risk of liability after the fact (Felsenthan, 1994). This risk 
of potential liability is magnified as legal uses and interpretations of EBM and 
other science-based medical evidence have potential to diverge from initial 
interpretation of that evidence by the medical and health care researchers who 
produced it to the practitioners and health plans that use the findings in making 
clinical decisions and policies (Havighurst et aI., 2001). 
Definition of evidence-based medicine. EBM is defined as the 
conscientious, explicit and judicious use of current best evidence in making 
decisions about the care of individual patients (Field & Lohr, 1990; Sackett et aI., 
1997). Emphasizing structured and critical examination of medical research to 
determine clinical effectiveness, EBM challenges consensus-based judgments 
and applies critical assessment to determine methodologically sound evidence 
and favorable clinical outcomes (Belkin, 1997). 
Physicians are encouraged to practice "evidence-based medicine," so that 
clinical decisions would be based upon a foundation of solid science, rigorous 
epidemiologic methods and published peer-reviewed findings. Moreover, there is 
a distinction between "efficacy," evidence of an effect under ideal conditions, 
such as in double-blind, randomized controlled trials, and "effectiveness," 
evidence of what actually works in clinical practice. Although this distinction is 
subtle, it is important for all users of evidence to understand, especially those 
who seek to use EBM to define medical quality (Roscoff, 2001). 
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Clinical practice guidelines - the origin of EBM. EBM has impacted 
medical practice largely through the development, dissemination, and use of 
clinical practice guidelines (Eisenberg, 1999). The Institute of Medicine's widely 
cited 1990 report defines clinical practice guidelines as systematically developed 
statements to assist practitioner and patient decisions about appropriate health 
care for specific clinical circumstances (Field & Lohr, 1990). These statements 
are used to guide practitioners undertaking treatment of vari0l:'s conditions and to 
help hospitals, third-party payers, regulatory bodies and practitioners determine 
whether care given in a particular instance was adequate and appropriate 
(Brennan, 1991). 
The Institute of Medicine's (10M) Committee on Clinical Practice 
Guidelines identified the attributes of good clinical practice guidelines almost a 
decade ago. The 10M evaluation instrument has been refined in the United 
Kingdom and Europe over the past eight years, and a multinational study of 
evaluative criteria for clinical practice guidelines is ongoing (Roscoff, 2001). 
Worldwide systems used in formulating guidelines differ in at least five respects, 
including methods for identifying, appraising, and ranking relevant research 
evidence; models for integrating indirect evidence; methods for incorporating 
experience and opinion; models for evaluating potential harm, cost and value; 
and sponsorship (Daly, 1995). Consequently, most guidelines are a complex 
amalgam of clinical experience, expert opinion and research evidence 
(Havighurst et aI., 2001). 
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Clinical practice guidelines are being developed through two distinct 
research techniques. The first class of clinical practice guidelines is developed 
through a consensus process where the treatment recommendations are a 
consolidation of reality-based inductive thought, contemporary belief and day-to-
day medical practice. The second class of guidelines is generated through more 
deductive and rigorous analysis of empiric outcomes data. While more 
technically correct and research based, this latter class of clinical practice 
guidelines, when first disseminated to the medical community, is much less likely 
to reflect current professional practice (Sackett & Guyatt, 1992) than it is 
representative of an ideal care process. 
Guidelines, when used to infer clinical quality, most often apply to the 
general and not the particular (Daly, 1995). Following evidence-based guidelines 
does not always assure good outcomes, just as diverging from guidelines does 
not always signal poor care (Field & Lohr, 1990). Each requires extrapolation to 
individual circumstance (Brennan, 1991). 
Medical standards of care. Unlike a guideline, which is a recommendation 
for best practice, medical standards are known practices that are medically 
necessary and services that any health care practitioner under any circumstance 
would be required to render (Havighurst et aI., 2001). Evidence-based guidelines 
focusing on single conditions likely will enhance, but not solely determine, 
standards of medical care in the United States. As well, research evidence alone 
will invariably be inadequate to establish medical standards, as standards require 
priority setting based on cost and value judgments (Field & Lohr, 1990; Sackett 
et aI., 1997). 
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Changing medical practice in response to EBM. The process of changing 
medical practice in response to EBM is gradual and fragmented (Eddy, 1996; 
Tanenbaum, 1994). In the short run, physicians' decisions are not likely to be 
greatly influenced by outcomes research. Physicians are inclined to be 
distrustful of such studies and the conclusions drawn from them (Tanenbaum, 
1994). Research evidence can be ambiguous and requires interpretation and 
judicious weighting of its significance (Eisenberg, 1999). Even when physicians 
accept research findings as accurate in general, they tend to find reasons to 
believe that their particular patient is atypical and, therefore, merits treatment 
different from that which might normally be indicated by the study findings 
(Selkin, 1997; Matthews, 1999; Tanenbaum, 1994). 
Despite physicians' assumption that their practice is rooted in empirical 
science, the past three decades have produced incontrovertible evidence that 
clinical practice deviates from research-based recommendations (Eddy, 1996). 
There is sufficient evidence to suggest that most clinicians' practices do not 
reflect the principles of evidence-based medicine but rather are based upon 
tradition, their most recent experience, what they learned years ago in medical 
school or what they have heard from their peers (Eisenberg, 1999). The average 
physician is said to read scientific journals approximately two hours per week, 
27 
and most are likely overwhelmed by the volume of material confronting them on a 
daily basis (Tannenbaum, 1994). 
Recent emphasis on evidence-based medicine and information systems 
has begun to promote the use of evidence in medical education programs 
(Sackett & Guyatt, 1992). Medical education as a whole now recognizes that no 
physician can know all the literature, but that through evidence-based practice 
physicians can judge the treatment and diagnostic options for the patient at hand. 
Thus the culture of medical education is moving toward building a base for 
practice grounded in science (Eisenberg, 1999). Practicing evidence-based 
medicine is not easy. No clinician alone can absorb and synthesize the vast 
amount of literature available, make judgments on its quality, and translate all 
findings into their clinical practice (Shuman, 2001). 
Many physicians decry the spread of clinical practice guidelines (and other 
forms of EBM) as the advent of "cookbook medicine," having the potential to 
lower the quality of health care by subordinating and subverting professional skill 
and judgment (Tanenbaum, 1994). Without question, today's clinical practice 
guidelines should not be viewed as conclusive evidence of the standard of care. 
No single authoritative guideline for medical conditions exists. For many 
conditions, there are multiple, and sometimes conflicting guidelines. As case in 
point, the American Cancer Society recommends yearly mammography, and the 
American College of Obstetricians and Gynecologists recommends "regular" 
mammography without specifying frequency_ Which of the two should be viewed 
as "more expert" (Roscoff, 2001; Eisenberg, 1999)? Physicians will have to 
engage in a process of deciding, when guidelines conflict on a material point, 
which one to treat as the more authoritative. The likely outcome is that, 
assuming each guideline meets minimum qualifications, both will be considered 
acceptable and medical practitioners will be left to choose between them -
perhaps with adequate wisdom, perhaps not (Anderson, Hall, & Smith, 1998). 
Creating A New Model of Care 
Managed care, case management, and disease (or disease state) 
management are all terms that refer to care delivery systems developed to 
manage high-cost patients or conditions. However, these terms, especially 
disease management, have been applied so loosely and to such a variety of 
activities over the years that they have lost much of their meaning. While these 
terms are often used interchangeably, they denote different methodological 
approaches to health care delivery and derive from different perspectives. 
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Managed care is a system of care focused on controlling the use of health 
care resources (Gardner & Scheffler, 1988). The term case management, in 
contrast, has been increasingly used to denote a patient care management 
mechanism that coordinates the complex health needs of individuals in an 
increasingly fragmented health care delivery system (Berkowitz & Halfon, 1992). 
The American Nurse Association defines case management as health 
assessment and planning, procurement, delivery coordination, and monitoring to 
ensure that the multiple needs of the client are met (Kurec, 1996). 
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Disease or disease state management differs in its approach from both 
managed care and case management. Disease management takes a systems 
approach to the management of moderately costly, relatively high prevalence 
chronic diseases, including such conditions as diabetes, cancer heart disease, 
and asthma. However, systematic care management, while an evolution of 
disease management and case management, is distinguished from both 
approaches in that it is a more comprehensive, collaborative, evidence-based 
and fiscally accountable model, for ongoing management of catastrophic injuries 
and conditions (Cope, Bryant et aI., 2001). 
Systematic Care Management (SCM) 
In response to the evident deficiencies of early management efforts as 
well as the enormous costs associated with both short- and long-term treatment 
of complex conditions, it is critical that a new management system be 
implemented that incorporates adequate clinical data capture and analysis, 
coupled with empirically derived managed principles (including but not limited to 
EBM). Such a system must also recognize the limitation of a purely data and 
science driven management approach, and integrate these where necessary with 
a structured approach based upon consensus expert clinical judgment. For the 
past decade, such a system (referred to as systematic care management) has 
been in development at ParadigmHealth (Cope, Bryant et aI., 2001). 
Insurers, employers, and managed care firms contract with 
ParadigmHealth to facilitate the care management process for catastrophic and 
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medically complex conditions (Carter et aI., 1999). The objectives are to reduce 
costly deviations in care, apply proven methods of treatment, enhance patient 
outcomes, and import expertise when care is being delivered in more remote 
settings using a collaborative, physician expert model (Cope, Nathan et aI., 
1995). 
SCM defined. Systematic care management (SCM) is a process of clinical 
and financial management of high-cost patients that focuses on 
comprehensiveness, coordination and integration (Cope, Bryant et aI., 2001). 
SCM supplements the basic principles of case management with fiscal 
accountability and the development and use of evidence-based, data-driven 
clinical pathways. Unlike traditional case management, SCM places value on the 
prevention of future adverse events by managing problems in a timely manner 
and slowing the rate of decline of patients with chronic conditions (Carter et aI., 
1999). 
The goal of SCM is to ensure that each catastrophically injured or 
chronically ill patient receives the most appropriate medical care required, 
allowing him or her to achieve the highest feasible clinical recovery, while at the 
same time minimizing the expenditure of inexpert, unnecessary or ineffective 
medical resources (Cope & O'Lear, 1993). There is now growing recognition that 
achieving these results requires integrated clinical and financial care 
management based on collaborative relationships, data-driven processes and 
fiscal accountability (Friedman et aI., 2002; Geyman, 2002). It has been 
suggested that achievement of both clinical and financial care goals are 
enhanced by some degree of risk transfer to the provider to ensure incentive 
alignment (Horn, Sharkey, Tracy et aI., 1996; Kurek, 1996; Miller & Luft, 1997. 
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Elements of SCM. The SCM process is both data and outcome driven and 
relies on clinical experts to apply a structured management approach across all 
cases (Cope, Nathan et aI., 1995). The principles that make this model of care 
management uniquely suited for the medically complex population follow: 
1. The provision of clinical expertise to col/aborative/y assist in the care 
process. Clinicians who are expert in the field are best suited to understand 
the clinical complexities of care for high-risk neonates (Cope & O'Lear, 1993). 
Using this logic, ParadigmHealth identifies and retains expert neonatologists, 
neonatal nurse practitioners, and neonatal clinical consultants to work as a 
team in managing cases. These clinicians collect, analyze and interpret the 
data and then work collaboratively with the attending physicians and nurses 
who are treating the infant to develop an effective and efficient care path. 
The Paradigm neonatal team provides support, education and consultation to 
the parents of the infant to assure that they are fully apprised of the care 
being provided and to assist them in preparation for discharge home. The 
team provides ongoing support to the family during the critical initial period at 
home post discharge from the NICU. On occasion, when clinically indicated, 
this core team is expanded to include pediatric surgeons, cardiologists or 
other subspecialties to consult with the ParadigmHealth team to assure 
optimal outcome achievement (Carter et aI., 1999; McLean et aI., 2002). 
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2. A data system that aggregates detailed relevant clinical and financial 
information to allow correlations of clinical conditions, medical management 
and financial and clinical outcomes. The Paradigm database and data 
collection tools are crucial to the prediction and management process and the 
care path development necessary to achieve a successful outcome. The 
clinical database has been built in collaboration with MillimanUSA and is 
comprised of approximately 320,000 neonatal cases from throughout the 
United States. The patients in the database include those managed by 
Paradigm as well as cases not managed by Paradigm (utilized for comparison 
purposes). The information included in the database ranges from discrete 
physiological measures to ICD-9 diagnosis and procedure codes, as well as 
detailed billed and paid NICU cost data (Cope, Bryant et aJ., 2001). 
3. Structured management processes which assure reliable and efficient 
application of clinical knowledge and care across multiple and extended 
clinical settings and over prolonged periods of time. These processes include 
a. The establishment of a specific outcome to be achieved in each case. 
For neonates, the outcome is successful discharge from the NICU with 
a minimum of 30 days of stability within the home environment; 
b. Standardized data collection tools that are utilized for all cases, 
therefore, the same data are available across all cases irrespective of 
diagnoses and severity; 
c. A proprietary Levels of Acuity system that is applied across all levels of 
severity of neonates. This system has five levels of care ranging from 
Extreme Care or ECMO to Continuing Care. It delineates the criteria 
that must be met for an infant to be assigned to a particular acuity level 
and also specifies the criteria the infant must achieve to move from 
one level of acuity to the next; 
d. Structured discharge criteria; and 
e. Standardized outcome achievement criteria, applied consistently 
across all diagnoses and severity of neonates (Carter et aI., 1999; 
McLean et aI., 2002). 
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Through the use of expert neonatologists, a collaborative process is 
created. Nurse practitioners are able to collect, analyze and interpret case-
specific data while applying a systematic set of management principles to the 
case. In addition, the clinical consultants and nurse practitioners work in a 
collaborative and collegial manner with the families and treating physicians of the 
high risk infants for purposes of family (parental) education and discharge 
planning (Cope, Bryant et aI., 2001; Gardner, 1999). See Appendix B. 
SCM: A Model Solution 
The SCM model is specifically designed to ensure that each provider 
along the continuum of care has the necessary expertise to identify and address 
the appropriate clinical problem(s) with the most efficient resource consumption 
in order to provide the optimal clinical outcome. SCM involves the following eight-
step process (Carter et aI., 1999; Gardner, 1999): 
• Step 1. High-risk maternity screening and consultation. The most cost-
effective care management of a high-risk neonate is prevention. A significant 
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impact, clinically and financially, can be made on the trajectory of care for an 
infant during the first few hours after birth, depending on the specifics of the 
delivery. The objective of this phase of care is to help the high-risk mother 
identify the most appropriate hospital for delivery (one capable of managing a 
high-risk neonate). 
• Step 2. On-site assessment. At the time of the NICU admission, a 
comprehensive on-site assessment is completed. The data from this 
assessment are entered into a system to be used in prediction, outcome plan 
development, and management of the critically ill newborn. 
• Step 3. Physician to physician communication. Using this initial data, the 
ParadigmHealth neonatologist communicates with the attending neonatologist 
to discuss the infant's trajectory of care, taking into consideration projected 
lengths of stay at each level of care within the NICU, specific clinical problems 
and risks that are anticipated in care management, and the overall plan of 
care to achieve an efficient, effective, and safe discharge home. 
• Step 4. Case conceptualization. Equipped with the data from the 
assessment, the care manager's observations, the neonatologist's 
information, and clinical impressions gleaned from the attending physician, 
the team conceptualizes the case, develops a budget to manage the case 
and compares this case information to similar cases in the SCM database. 
• Step 5. Finalization of the outcome plan. After further data are obtained 
regarding questions or issues generated during step 4, a final outcome plan 
and budget to achieve that outcome are developed. 
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• Step 6. Clinical management focus. Once the outcome plan is in process, 
the team meets on a regular basis to review key components of the case, 
including the status of clinical problems and risks, the provider's relationship 
and alignment, the family's understanding regarding the infant's projected 
needs and their preparation to meet those needs, and the budget status. 
From this, the team is able to identify the focus of clinical management for the 
next reporting period. 
• Step 7. Discharge planning. While discharge planning begins the day of 
NICU admission, s specific tool is used to enhance this process and ensure 
that all the details are addressed to facilitate a timely discharge. In addition, 
discharge criteria are reviewed at each clinical team meeting. 
• Step 8. Outcome achievement. The outcome achievement criteria are 
reviewed at each clinical team meeting, and, once the criteria are met, a 
.. " 
report is prepared to document the supporting evidence for achievement of 
the outcome plan. This report is presented to the health plan (or employer) 
client for their concurrence and audit, and then the case closure process 
begins. 
A unique feature of the SCM model is that the PMDs have no direct role in 
patient treatment or coverage decisions and, hence, should not artificially restrict 
resources for a given patient (Bryant, 2002). The focus is not to simply reduce 
the patient's length of stay in the NICU, but to collaborate with the attending 
physician in orchestrating effective outcome management (Cope, Bryant et aI., 
2001). This is accomplished through 
1. Collecting data directly from the attending physicians; 
2. Providing clinical and scientific expertise to the clinical team; and 
3. Analyzing data and clinical events. 
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The SCM team includes registered nurses or nurse practitioners with 
extensive clinical and care management expertise, especially in the management 
of neonatal complications or complex medical injuries/events (Bryant, 2002). 
They are either under contractual arrangement with the company or are 
employees, and provide either telephonic or on-site independent assessment 
and management. In addition to providing actual case management, the team 
nurses complete the data-collection tools that are the foundation for the SCM 
database (Cope, Nathan et aI., 1995). 
The SCM model is a collaborative system for managing very complex 
patient care and recovery across the continuum of care, providing oversight, 
access to data on outcomes of various treatment choices, and a broader level of 
expertise in its program providers (Gardner, 1999). ParadigmHealth provides the 
attending physician with external expertise, which can either supplement the 
attending physician's skills and knowledge base or confirm the appropriateness 
of the care being provided. The attending physician is empowered to establish 
the appropriate allocation of resources and gains a greater understanding of total 
costs compared to traditional systems. Through this feedback mechanism, the 
SCM model provides a powerful foundation for understanding the consequences 
of care decisions for complex medicine. The SCM model contributes to the 
health care process, following Eddy's suggestion, 
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The solution [to practice variability] is not to remove the decision-making 
power from physicians, but to improve the capacity of physicians to make 
better decisions. To achieve this solution, we must give physicians the 
information they need; we must institutionalize the skills to use that 
information; and we must build processes that support, not dictate, 
decisions. (Eddy, 1996, p. 8) 
Under the SCM model, the patient and their course of care are 
continuously and comprehensively managed from the date of the initial onsite 
through completion of the outcome plan and case closure, or until the case is 
formally returned to the health plan for their internal management (Carter et aI., 
1999). This pattern of aggressive, timely on-site and telephonic care 
management, consistently applied throughout the entire course of the outcome 
plan, allows ParadigmHealth to intervene in the most appropriate fashion with 
minimal delay, thereby promoting an optimal course of recovery for the patient. 
To facilitate communication of the patient's progress, the SCM model includes a 
battery of written reports, telephonic updates, and internal teleconferences that 
provide consistent, timely and accurate information on the patient's status 
(Bryant, 2002). These set the foundation for a system of communication and 
accountability for the stakeholders (Cope, Bryant et aI., 2001). 
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SCM tools. To facilitate objectivity, ParadigmHealth uses data tools that 
permit objective comparisons of current case data with past performance, with 
statewide and national data, and with expert clinical judgment (Gardner, 1999). 
The internal data capture tool from which all other individual case specific data is 
extracted contains over 500 variables and provides the CMT with the necessary 
clinical, demographic, provider, and health plan information to begin 
management of the case and development of an outcome or clinical 
management. 
Another major internal tool used in budget development is the "Complexity 
Calculator." This Complexity tool is a risk-adjustment strategy that is data based 
and consists of a statistically derived set of diagnosis specific variables and their 
assigned multiple regression beta weights (Bryant, 2002). The diagnosis-specific 
variables were initially selected through the use of a modified Delphi 
methodology (Normand, McNeil, Peterson, & Palmer, 1998; Turoff & Hiltz, 1996) 
using groups of physician experts from each diagnosis-related field. The 
statistically derived variable set along with financial data were then entered into a 
regression analysis in order to develop a set of weights for the variables that 
would best predict resource consumption (length of stay and total costs) for each 
diagnosis (for the Neonate Complexity Calculator, both internal data and data 
from the California Office of Statewide Health Planning and Development were 
used.) Multiple regression scores were then grouped (by the level of resources 
consumed) in order to establish a resource utilization scale for the SCM model. 
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To provide an estimate of external validation for the Complexity construct, 
the same set of variables and data were given to a second set of physician 
experts who were "blind" to the statistical Complexity projections. These 
physician experts were then asked to make their own assessment of severity and 
probable resource utilization and to assign their own complexity level of each 
case. Subsequent correlation analysis revealed a 0.9 or greater correlation 
between the Complexity Calculator estimates and those of the physician experts. 
Such high correlations suggest that the Complexity Calculator does provide a 
reliable estimate of severity and support the concept of the Complexity Calculator 
as a reliable predictor of resource consumption (Bryant, 2002). 
The third set of budget development tools is two statistical tables derived 
from the ParadigmHealth internal database. These tables provide the DCS with 
actual data from prior, similar ParadigmHealth cases to which the current case 
can be compared. 
Application of a modified De/phi methodology in SCM. SCM was 
designed as a management model that is both database driven and "clinical 
expert" driven. To ensure that the clinical expert component was statistically 
grounded, a modified Delphi Methodology was employed whenever clinically and 
medically complex forecasting strategies needed to be developed. Helmer 
(1983) of the Rand Corporation originally developed the Delphi Methodology, a 
structured, multi-pass group decision process designed to address problems that 
require professional expertise to achieve resolution, in the 1950's for 
technological and military forecasting (Linstone & Turoff, 1975). In the ensuing 
40 years the approach has commonly been adopted in medicine, nursing, 
psychology, and health care. The object of the Delphi method is to 
40 
systematically obtain reliable responses to complex problems from a group of 
experts (Helmer, 1983; Normand et aI., 1998). As such, it recognizes human 
judgments as legitimate and useful inputs for generating forecasts. The process 
involves giving the panel of experts a series of questionnaires or interviews in an 
iterative fashion while providing them with controlled opinion feedback about their 
own and the other experts' responses after each data gathering session (Turoff & 
Hiltz, 1996). The process has the following three core elements: 
1. Structuring of information flow; 
2. Feedback to the participants; and 
3. Anonymity for the participants (that is, each participant's responses are 
kept anonymous relative to the other members of the panel, thereby 
preventing the "halo" effect.) 
The SCM model has employed a modified Delphi Methodology primarily in 
the areas of severity risk-adjustment (development of the Complexity Calculator) 
and in estimating cost-savings through medical complication prevention (Cope, 
Bryant et aI., 2001; Bryant, 2002). As mentioned previously in this paper, severity 
risk-adjustment is a complex process at best; yet it is essential when comparing 
patient populations, especially across cost and outcome parameters, which are 
highly susceptible to even minor variations in medical severity. To address this 
issue, ParadigmHealth used a panel of clinical experts in the fields of 
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rehabilitation, physical medicine, orthopedics, trauma, burns, and neonatology 
and employed a modified Delphi Method to develop a list of those variables for 
each diagnosis which they expected to be most directly related to resource 
utilization (McLean et al., 2002). The panel of experts was selected based upon 
those variables, along with cost and length of stay data (and for neonates 
appropriate data from the state and national databases as well). They were then 
entered into a series of regression analyses, from which ranges for Complexity 
Levels were established. Subsequent to completion of that initial research, a 
Complexity Level has been calculated and recorded in the ParadigmHealth 
database for all patients with risk-bearing contracts. Over time the database has 
grown substantially in size. To further improve precision in resource utilization 
prediction, this larger database has then been used to re-calculate the beta 
weights for all of the variables (Bryant, 2002). 
ParadigmHealth has also used a modified Delphi Methodology in 
developing two other (Bryant, 2002) savings estimates: 
1. Selection of the primary risks related to a given diagnosis and in 
setting differential levels of resource utilization depending upon the 
severity of risk expression, and 
2. Setting estimates of cost savings when neonates are placed in facilities 
that support ParadigmHealth's SCM model versus being placed in 
those facilities that choose to not participate. 
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A panel of experts for each diagnosis was chosen with the project 
coordinator serving as leader/facilitator. Panelists were from various medical 
facilities across the country and participated telephonically and via e-mail. 
Anonymity in the response summary was maintained. Over the course of 2-3 
iterations members of each of the panels were able to come to mutual agreement 
on their respective core issues (Bryant, 2002). 
It should be stated that the Delphi Methodology has its limitations as a 
research technique; specifically, (a) problem selection needs to be restricted to 
those decisions that lend themselves to the use of group involvement; (b) the 
process is iterative and as such can take significant time to complete, especially 
if panel members have limited time to invest in the process; and (c) finding a 
panel of experts can be challenging for some topics. Nonetheless, the Delphi 
technique has reached a stage of maturity and continues to be actively used in 
health care research due to the complexity of health care issues. It is 
ParadigmHealth's contention that, since the savings estimates described above 
were developed systematically using the Delphi methodology, in so far as 
ParadigmHealth can demonstrate that through its actions a given risk either did 
not become an active problem or its expression was milder than it would have 
been without the firm's management, or that a length of stay at a specific level of 
care was reduced through implementation of the SCM model, then 
ParadigmHealth can accurately assert that the dollars associated with that risk 
and severity level or length of stay are true cost savings (Cope, Bryant et aI., 
2001 ). 
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The Evidence for SCM 
The objective of systematic care management is to scientifically refine 
care processes over time by iteratively examining relationships between process 
and outcome, eliminating inappropriate services, and enhancing both the 
efficiency and the outcome of the care that is delivered. There is evidence that 
early iterations of this model of care have been effective; i.e., that when 
timeliness and expertise were introduced into the care of catastrophically injured 
patients, significant cost reductions resulted (Cope & Q'Lear, 1993; Gardner, 
1999; McLean et aI., 2002). 
The components of SCM include provider selection and education; 
comprehensive assessment and treatment plans; an emphasis on patient-
specific outcomes extending beyond the acute phase into community re-
-
integration; development, use and re-evaluation of clinical guidelines and 
protocols; and data-driven evaluation of cost effectiveness and the relationships 
between process and outcome (Cope & O'Lear, 1993; Cope, Bryant et aI., 2001). 
In typical managed care systems, utilization review and other attempts to 
address medial necessity have been hampered by a lack of evidence about the 
differential effectiveness of alternative clinical pathways; establishing clinical 
guidelines has been stymied by the lack of clearly defined outcome measures; 
and most quality assurance requirements have focused on the processes of care 
not on the outcomes of the care received. For catastrophic injuries where care 
extends over a longer term, it is essential that the focus of quality include the 
outcomes of care and the relationship of outcomes to processes (Bryant, 2002; 
Gardner, 1999). 
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The key to the effectiveness of the SCM model is the combination of 
clinical evidence and data on patient characteristics and costs (Carter et al., 
1999). SCM is differentiated by its long-term, comprehensive, provider-
collaborative, data-driven approach to care. It utilizes the available evidence 
about alternative clinical practices and their costs as well as their immediate and 
long-term outcomes and costs. It takes into account the full continuum of 
necessary services over the patient's entire episode of care (and often remaining 
life span) in assessing the relative utility of alternative therapies. 
A feasibility assessment of the SCM model confirmed the health care 
industry's readiness to adopt such a system (Cope & O'Lear, 1993; Jencks, 
1997). Another assessment of the potential of a SCM model found that 
purchasers, providers, payers, consumers and policymakers alike support a 
system that is based on results not just processes of care (Jencks, 1997). 
III. Methodology 
This study will quantitatively compare neonatal average lengths of hospital 
stays (ALaS) and length of stay range between the ParadigmHealth dataset and 
the MillimanUSA dataset (MillimanUSA, 2002). The study will duplicate the same 
comparison between the ParadigmHealth dataset and the dataset from 
California's Office of Statewide Planning and Development (OSHPD, 2002). 
The OSHPD dataset is a subset of the MillimanUSA dataset. This 
secondary comparison is being done due to the linking of transfer cases that are 
unique to the California dataset. Researchers at Stanford University 
methodically matched transfer cases so that infants transferred from one NICU 
setting to another were counted as one complete case rather than two separate 
patients (Phibbs, Bronstein et aI., 1996). The results of this linking process have 
been used to adjust the larger MillimanUSA dataset to account for these transfer 
cases. The aim of the study is to determine whether ParadigmHealth's 
Systematic Care Management (SCM) process reduces average length of stay 
(ALOS) in the NICU population. In addition, the researcher would like to 
determine whether the SCM process also reduces the range in the total LOS for 
the high-risk neonate population. 
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Data Classification and Framework 
The study will use data derived by ParadigmHealth's management of 
NICU cases for a three-year period (1998 - 2000), data obtained from 
MillimanUSA for the same period sourced from the Health care Cost and 
Utilization Project (HCUP), and data obtained as a subset of the MillimanUSA 
dataset from the California's Office of Statewide Planning and Development 
(OSHPD) for the same period. These datasets have been compiled using the 
patient classification system that was developed by 3M Health Information 
Systems (3M, 1995) referred to as the APR-DRGs (All Patient Refined Diagnosis 
Related Groups). This classification system is modeled after the All Patients 
Diagnosis Related Group (AP-DRG) system. This classification system uses 
hospital patient discharge data and computer-based logic to assign patients to 
severity of illness and risk of mortality classes so that they can be accurately 
compared in terms of length of stay, resource consumption and outcomes (Averill 
et aI., 1997). This APR-DRG system was developed as a joint venture between the 
New York Department of Health and 3M Health Information Systems as a result of 
1987 state legislation that stipulated the development of a DRG-based prospective 
payment system for the payment of all non-Medicare patients. The All-Patient DRG 
system (AP-DRG) was developed for this purpose and then refined in 1990 (APR-
DRG) as a better measure for not only resource intensity, but also matching 
resource intensity with severity of illness and risk of mortality. Three subsequent 
updates to the classification categories have been released since 1990 with the 
latest being completed in 1998 (3M, 1995). In refining the system to include severity 
and mortality adjustment factors, it is now possible to use these patient 
classifications for endeavors such as the following: 
• Comparing hospitals across a wide range of resource and outcome 
measures, 
• Evaluating differences in inpatient mortality rates, 
• Assessing possible causes for variation to develop evidence-based 
best practices, 
• Implementing and monitoring the success of clinical pathways, 
• Providing individual or group profiles and opportunities for objective 
feedback, 
• Identifying areas for continuous quality improvement initiatives, 
• Identification of patients benefiting from case management, and 
• Improving the quality of care (Averill et aI., 1997). 
There are 6 total All-Patient DRG's that deal with non-normal newborns. 
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The APR-DRG's add a much greater level of granularity by expanding the 
number of classes from these 6 neonate AP-DRG's to 35 neonate APR-DRG's. 
Further, the APR-DRG system adds four subclasses to this framework, 
incorporating severity of illness and risk of mortality to address patient 
differences and allow for superior severity adjustment within APR-DRG 
classifications (See Table 1). The four subclasses are numbered sequentially 
from 1 to 4 and indicate minor, moderate, major or extreme severity of illness or 
risk of mortality. Thus, via the APR-DRG system's decision-tree methodology, 
each patient is assigned three distinct descriptors: base APR-DRG, severity of 
illness subclass, and risk of mortality subclass (e.g. 590-4-3 would be a baby 
with a birthweight of less than 750 grams with major procedures, a severity of 
illness within that classification of 4 and a risk of mortality of 3). 
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APR-DRG Version 15.0, the most recent version of the software (3M, 
1995), utilizes 357 diagnostic related groups (DRG's), each with four severity of 
illness subclasses and four risk of mortality subclasses for a total of 1422 APR-
DRG's. This is the most comprehensive and widely used patient classification 
system in existence. 
A major investigation was conducted in which 4,203,646 hospital 
discharge records of patients were analyzed and a comparison was made of the 
DRG system versus the APR-DRG system for predictive accuracy of patient 
costs (Averil et aI., 1997). The predictive accuracy of the APR-DRG system was 
30.3% higher than that of the DRG sysfem. 
For neonatal services, there are 33 primary diagnostic categories with four 
severity levels for each of these categories, resulting in 132 APR-DRG severity 
classifications or groupers. The four severity levels are based upon the number 
of secondary ICD-9 diagnostic and procedures codes as well as the interaction 
between these ICD-9 codes. This process is captured algorithmically in the 3M 
model. The determination of the specific APR-DRG category that is assigned to 
a patient is made based on the hospital discharge billing form (known as the U8-
92 form) submitted by the treating hospital. The base APR-DRG, severity of 
illness and risk of mortality subclass determination is a three-phase process, 
wholly contained within the 3M model protocols. 
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For the ParadigmHealth dataset, inputs the demographic information and 
all known ICD-9 diagnosis and procedure codes were done to allow the grouper 
software to accurately and finely determine the APR-DRG and subclasses. As 
mentioned, the first phase begins as the grouper software assigns the base APR-
DRG. The severity of illness and risk of mortality subclass determination is 
completed during the second and third phase respectively, in which the 
classification system takes into consideration factors such as age, principal 
diagnosis, operating and non-operating procedures present, interaction among 
and combinations of categories of secondary diagnoses in making the final 
determination (McLean et aI., 2002). 
The final determination of APR-DRG classification for each neonatal 
referral is based on discharge information readily available on the UB-92, such 
as primary and secondary diagnoses, and principal and secondary procedure 
codes. Paradigm utilizes the 3M Grouper Software to objectively assess APR-
DRG classification at the time of referral to get a picture of severity, risk of 
mortality and potential resource utilization; however, additional procedures and 
secondary diagnoses only available at discharge, will ultimately affect the final 
determination of the APR-DRG base group and severity of illness and risk of 
mortality classifications (Bryant, 2002). 
50 
Aims of the Study 
This study had two primary goals: 
1. To determine whether the SCM process of management is associated 
with significant reductions in the average length of stay (ALOS) of 
complex, high-risk neonates during their initial NICU hospitalization. 
2. To determine whether SCM is effective in reducing the range in NICU 
lengths of stay within APR-DRG groups. 
Primary Research Question 
ParadigmHealth's Systematic Care Management (SCM) is a process 
specifically designed to address the challenge of extremely complex medical 
problems (Bryant, 2002; Gardner, 1999). This care process is different from 
existing methods of management in that it is data driven, provider collaborative, 
and outcome focused (Bryant, 2002; Gardner, 1999; McLean et aI., 2002). This 
analysis will address the question "is there quantitative support that such 
management results in a reduction in ALOS as well as a reduction in the range of 
patient length of stay in the high-risk neonate population?" 
Research Hypotheses 
The study had two primary hypotheses: 
H1: There is evidence that ParadigmHealth's Systematic Care 
Management (SCM) process results in a reduction in NICU average 
length of stay (ALOS). 
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H2: There is evidence that the SCM process reduces the range of 
patient length of stay) in the high-risk neonate (NICU) population. 
Null Hypotheses 
Following the two hypotheses presented above, there were two null 
hypotheses under study: 
Ho1: There is no evidence that ParadigmHealth's Systematic Care 
Management (SCM) process results in a reduction in NICU average 
length of stay (ALOS). 
Ho2: There is no evidence that the SCM process reduces the range of 
patient length of stay) in the high-risk neonate (NICU) population. 
Study Design and Analysis 
A t-test is utilized to test for statistically significant differences in the 
means between the ParadigmHealth dataset and the two comparison datasets. 
The individual APR-DRG means of the Paradigm dataset will be compared to the 
means for the MillimanUSA dataset and the OSHPD dataset Using SAS (1986) 
tools, the analysis will produce two t-test, the relevant one depending on whether 
the differences are equal or unequal. A folded F-test is utilized to test the equality 
of variance. This equality of variance test illuminates the reasonableness of the 
assumption of equal variances versus unequal variances for these datasets, 
given a normal distribution. The folded F-test is a test of the results of a 
statistical analysis, perhaps most closely associated with, but by no means 
limited to, analysis of variance. If the F-test has a significant p-value (P < .05), 
then the t-test for unequal variances will be used to evaluate the APR-DRG. If 
the F-test produces a p-value greater than .05, the t-test for equal variances will 
be used to evaluate the APR-DRG. 
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If the equality of variances illustrates the reasonableness of equal 
variances, then the appropriate statistical test for this analysis is the pooled t-test, 
which tests the assumption of equal variances. If the equality of variances 
illustrates the unreasonableness of equal variances, then the appropriate 
statistical test for this analysis is the Satterthwaite test (Satterthwaite, 1946), 
which tests for the hypothesis of unequal variances. 
Acknowledging that probability is a continuum, if p-value >= .05, then it is 
likely that the differences are not statistically significant to support unequal 
variance in t-test. If, however, the p-value < .05, then it is likely that the 
differences are unequal between the sa~mples. Since the statistical significance 
is a continuum (.05 is an arbitrary cut point) and the ParadigmHealth database 
contains certain APR-DRG cells that have relatively small sample sizes, it is 
possible that a p-value between .05 and .1 could be significant if the difference 
between the two means is relatively large. 
Paradigm Sample 
The Paradigm sample of cases is comprised of over 500 infants referred 
to ParadigmHealth from 1998 through 2000. These neonates represent a broad 
spectrum of clinical severity, comprising 82 distinct APR-DRG I Severity 
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combinations from 40 states. (There are 132 total possible distinct APR-DRG I 
Severity combinations.) While the top five referring states represent 850/0 of the 
ParadigmHealth dataset, they are geographically dispersed, including California, 
New Mexico, Texas, Wisconsin, and Pennsylvania. The sample is balanced 
between males and females with males representing 52% of the dataset. 
In some instances, a ParadigmHealth case may be included in one or both 
of the other two datasets. ParadigmHealth's California cases will be included in 
the OSHPD dataset and the MillimanUSA dataset. In addition, non-California 
ParadigmHealth cases originating from one of the states that participate in the 
Healthcare Cost and Utilization Project (HCUP) database from the Agency for 
Healthcare Research and Quality will be counted in the MillimanUSA dataset as 
well as this is the primary source for the MillimanUSA dataset. 
Comparison Sample 
The primary comparison sample to be used is the MillimanUSA dataset. 
The most extensive national neonatal database currently available, the 
MillimanUSA dataset's principal underlying data source is the Healthcare Cost 
and Utilization Project (HCUP) database from the Agency for Healthcare 
Research and Quality. This nationwide inpatient sample (NIS) contains data from 
approximately 7 million hospital stays. 
The NIS contains all discharge data from approximately 1,000 hospitals 
located in 22 States, approximating a 20-percent stratified sample of U.S. 
community hospitals. There are a total of 3,707,351 births in this sample and 
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318,249 NICU cases. For this study, a sub-sample of the NICU total cases will 
be used, which will be matched to the ParadigmHealth sample by APR DRG 
classification (for the 82 distinct severity combinations within the ParadigmHealth 
dataset). This sample will include approximately 130,000 NICU cases from the 
MillimanUSA dataset. The information included in the dataset ranges from 
discrete physiological measures to ICD-9 diagnosis and procedure codes, as well 
as detailed billed and paid NICU cost data. 
A secondary comparison sample will be data from the California data from 
the Office of Statewide Planning and Development (OSHPD). This database 
enhances the MillimanUSA dataset by providing more clinical information and 
allowing for tracking of neonates who transferred from one acute facility to 
another in order to fully estimate the length of stay associated with a given birth 
episode. This second comparison sample is utilized as a separate control group 
against which to compare ParadigmHealth's dataset. . This sample will include 
approximately 22,000 NICU cases from the OSHPD dataset. 
Delimitations 
This study effort may be limited by the nature of the research datasets used 
in this analysis. In order to control for facility coding and billing practices of 
providers within its database, the MillimanUSA dataset excludes neonatal deaths 
and infants discharged from the NICU within 5 days of admission, as such short 
stays are not representative of the general neonatal intensive care population. 
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In addition, while nationally recognized as the best severity adjustment 
parameter currently available in neonatal care, the APR-DRG weighted score for 
a patient may be influenced by human error in the classification and recording of 
secondary diagnosis and procedure codes. Each APR-DRG and its 
corresponding severity modifiers are derived by the combination of diagnostic 
and procedure codes created on the hospital billing form (UB-92). 
This research assumes the presence of nationally accepted evidence-based 
protocols for the care of high-risk infants in neonatal intensive care. The real 
world variability in neonatal intensive care practices (and their resultant 
outcomes) across facilities, regions and the nation present a limitation and 
challenge to this research effort. 
Finally, use of the MillimanUSA dataset and the California OSHPD dataset 
as a convenience sample for this study, while robust, may not represent the 
actual practice patterns of the nation's NICUs .. As such, conclusions drawn for 
this study may have limited applicability or clinical relevance to nation-wide 
neonatal intensive care practice. 
While both datasets include infant transfers among NICUs, the transfer 
cases within the MillimanUSA set are linked using the results of the California 
data from the Office of Statewide Planning and Development (OSHPD). This 
OSHPD dataset enhances the MillimanUSA dataset by providing a methodology 
to assume the proportion of neonates within the MillimanUSA dataset who 
transferred from one acute facility to another. The transfer rates from the 
OSHPD dataset are used to accurately estimate the acute length of stay 
associated with a given birth episode for neonatal cases in the MillimanUSA 
dataset. 
Birlhweight Categories and Sample Sizes 
A listing of the Neonatal APR-DRG codes and descriptions is provided in 
Table 1. These APR-DRGs are grouped into the following birthweight 
categories: 
• ECMO Procedures 
• Infants with Birthweight < 750 Grams 
• Infants with Birthweight 750 - 999 Grams 
• Infants with Birthweight 1000 - 1499 Grams 
• Infants with Birthweight 1500 - 1999 Grams 
• Infants with Birthweight 2000 - 2499 Grams, and 




APR-DRG Classification Description 
Severity Scale 
APR-DRG Description of Neonate APR-DRG 1 234 
580 Neonate, Transferred < 5 days old, not born here 
581 Neonate, Transferred < 5 days old, born here 
582 With organ Transplant 
583 With ECMO 
590 Birthweight < 750G w major procedure 
591 Birthweight < 750G w/o major procedure 
592 Birthweight 750G-999G w major procedure 
593 Birthweight 750G-999Gw/o major procedure 
600 Birthweight 1 000-1499G w major procedure 
601 Birthweight 1000-1499G w major anomaly or hereditary condition 
602 Birthweight 1000 .. 1499G w respiratory distress syndrome 
603 Other Birthweight 1000-1499G 
610 Birthweight 1500-1999G w major procedure 
611 Birthweight I 500-1999G w major anomaly or hereditary condition 
612 Birthweight 1500-1999G w respiratory distress syndrome 
613 Birthweight 1500-1999G w congenital or perinatal infection 
614 Other Birthweight 1500-1999G 
620 Birthweight 2000 ... 2499G w major pr5>cedure 
621 Birthweight 2000-2499G w major anomaly or hereditary condition 
622 Birthweight 2000-2499G w respiratory distress syndrome 
623 Birthweight 2000-2499G w congenital or perinatal infection 
624 Birthweight 2000-2499G not born here 
625 Birthweight 2000-2499G born here, w other significant condition 
626 Birthweight 2000-2499G, born here, normal nb & nb w other probs 
630 Birthweight >2499G, w major cardiovascular procedure 
631 Birthweight >2499G w other major procedure 
632 Birthweight >2499G w other procedure 
633 Birthweight >2499G w major anomaly or hereditary condition 
634 Birthweight >2499G w respiratory distress syndrome 
635 Birthweight >2499G W aspiration syndrome 
636 Birthweight >2499G W congenital or perinatal infection 
637 Birthweight >2499G not born here, w other significant conditions 
638 Birthweight >2499G, not born here, w other problems 
639 Birthweight >2499G, born here, w other significant conditions 
640 Birthweight >2499G, born here, normal nb & nb w other probs 
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A listing of those APR-DRGs included in the study for ECMO procedures 
is shown in Table 2. This special category is established for those infants with 
such significant respiratory distress that an ECMO procedure (surgical 
intervention to stimulate lung development) is performed. 
Table 2 
Sample Size for Birthweight Group with ECMO 
Birthweight: ECMO Procedures Total n for Birthweight Class 
APR-
Paradigm OSHPD Milliman Paradigm OSHPD Milliman 
DRG 
583/2 2 8 74 
583/4 4 0 40 6 8 114 
A listing of those APR-DRGs included in the study for the second 
birthweight category, those with birth weights < 750 grams, is shown in Table 3. 
There are 32 ParadigmHealth cases, 255 OSHPD cases, and 3,478 
MillimanUSA cases in this birthweight category. 
Table 3 
Sample Size for Birthweight Group < 750 Grams 
Birthweight: < 750 Grams Total n for Birthweight Class 
APR-
Paradigm OSHPD Milliman Paradigm OSHPD Milliman DRG 
590/3 1 3 40 
590/4 7 58 669 
591/3 1 19 271 
591/4 23 175 2498 32 255 3478 
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A listing of those APR-DRGs included in the study for the third birthweight 
category, those with birth weights ranging from 750 to 999 grams, is shown in 
Table 4. There are 58 ParadigmHealth cases, 493 OSHPD cases, and 6,148 
MillimanUSA cases in this birthweight category. 
Table 4 
Sample Size for Birthweight Group 750 - 999 Grams 
Birthweight: 750 - 999 Grams Total n for Birthweight Class 
APR-
Paradigm OSHPD Milliman Paradigm OSHPD Milliman 
DRG 
592/4 13 47 550 
593/2 1 27 442 
593/3 12 77 1219 
593/4 32 342 3937 58 493 6148 
A listing of those APR-DRGs included in the study for the fourth 
birthweight category, those with birth w~ights ranging from 1,000 to 1,499 grams, 
is shown in Table 5. There are 145 ParadigmHealth cases, 1,627 OSHPD 
cases, and 18,067 MillimanUSA cases in this birthweight category. 
60 
Table 5 
Sample Size for Birthweight Group 1000 - 1499 Grams 
Birthweight: 1000 - 1499 Grams Total n for Birthweight Class 
APR-
Paradigm OSHPD Milliman Paradigm OSHPD Milliman 
DRG 
600/3 1 1 95 
600/4 5 54 457 
601/1 1 6 78 
601/3 6 70 906 
601/4 4 106 853 
602/1 1 21 276 
602/2 10 70 1264 
602/3 33 268 3350 
602/4 37 302 2962 
603/1 6 127 1065 
603/2 9 288 3404 
603/3 18 204 2483 
603/4 14 110 874 145 1627 18067 
A listing of those APR-DRGs included in the study for the fifth birthweight 
category, those with birth weights ranging from 1 ,500 to 1,999 grams, is shown in 
Table 6. There are 147 ParadigmHealth cases, 3,604 OSHPD cases, and 
37,616 MillimanUSA cases in this birthweight category. 
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Table 6 
Sample Size for Birthweight Group 1500 - 1999 Grams 
Birthweight: 1500 - 1999 Grams Total n for Birthweight Class 
APR-
Paradigm OSHPD Milliman Paradigm OSHPD Milliman 
DRG 
610/2 1 2 47 
610/3 1 14 134 
610/4 4 29 297 
611/1 1 38 395 
611/2 1 79 1075 
611/3 3 93 1007 
611/4 10 52 401 
612/1 2 109 1133 
612/2 12 204 2345 
612/3 24 285 3106 
612/4 12 132 1208 
613/2 2 127 1510 
613/3 1 162 1774 
613/4 4 33 268 
614/1 27 1055 10842 
614/2 17 946 £}740 
614/3 18 210 2083 
614/4 7 34 251 147 3604 37616 
A listing of those APR-DRGs included in the study for the sixth birthweight 
category, those with birth weights ranging from 2,000 to 2,499 grams, is shown in 
Table 7. There are 55 ParadigmHealth cases, 4,294 OSHPD cases, and 29,086 
MillimanUSA cases in this birthweight category. 
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Table 7 
Sample Size for Birthweight Group 2000 - 2499 Grams 
Birthweight: 2000 - 2499 Grams Total n for Birthweight Class 
APR .. 
Paradigm OSHPD Milliman Paradigm OSHPD Milliman 
DRG 
620/4 3 34 310 
621/1 1 47 507 
621/2 1 96 973 
621/3 5 77 724 
621/4 4 33 227 
622/1 2 158 1527 
622/2 5 216 2320 
622/3 3 196 2144 
622/4 4 85 670 
623/1 2 138 1524 
623/2 1 147 1630 
623/3 3 201 1858 
625/1 3 876 7549 
625/2 1 354 2790 
625/3 7 141 1105 
626/2 4 635 J 191 
626/3 6 860 2037 55 4294 29086 
A listing of those APR-DRGs included in the study for the seventh 
birthweight category, those with birth weights> 2499 grams, is shown in Table 8. 
There are 89 ParadigmHealth cases, 11 ,922 OSHPD cases, and 42,622 
MillimanUSA cases in this birthweight category. 
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Table 8 
Sample Size for Birthweight Group> 2499 Grams 
Birthweight: > 2499 Grams Total n for Birthweight Class 
APR- Paradigm OSHPD Milliman Paradigm OSHPD Milliman DRG 
630/4 10 49 600 
631/2 4 59 829 
631/3 6 67 1074 
631/4 11 84 1357 
632/2 1 23 280 
632/3 1 28 394 
632/4 1 14 279 
633/1 1 162 1581 
633/3 4 273 3116 
633/4 8 113 1370 
634/2 2 638 5369 
634/3 2 477 4910 
634/4 5 197 2104 
635/3 2 264 1995 
635/4 2 72 552 
636/2 1 737 ~7892 
636/4 3 88 987 
639/1 4 1117 1681 
639/2 3 1221 2115 
639/3 8 436 989 
639/4 3 40 201 
640/1 2 2306 720 
640/2 2 2000 1137 
640/3 3 1457 1090 89 11922 42622 
IV. Results 
While the datasets all represent neonatal admissions, the distribution of the 
cases across the various APR-DRGs (as well as across the corresponding 
weight groups) varies, as shown in Table 9. The ParadigmHealth dataset 
contains a total of 532 cases, the OSHPD dataset 22,203 cases, and the 
MillimanUSA dataset 127,131 cases. 
Table 9 
Distribution of Cases by Birlhweight 
Paradigm OSHPD Milliman 
Health (CA) USA 
Sam~le Size 
ECMO 6 8 114 
< 750 G 32 255 3,478 
750 - 999G 58 493 6,148 
1000 - 1499G 145 1,627 18,067 
1500 - 1999G 147 3,604 37,616 
2000 - 2499G 55 4,294 29,086 
>2499G 89 11,922 42,622 
Total Sample Size 532 22,203 137,131 
The ParadigmHealth dataset contained a greater proportion of cases in 
the smaller birthweight groups (Table 10). For the ParadigmHealth dataset, the 
ECMO category (those infants with severe respiratory distress) represented 
1.130/0 of the dataset while only 0.04% for the OSHPD dataset and 0.080/0 for the 
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MillimanUSA dataset. Infants weighing less than 1000 grams, and the most 
medically fragile group of neonates, represented 16.920/0 of the ParadigmHealth 
dataset, 3.37% of the OSHPD dataset, and 7.120/0 of the MillimanUSA dataset. 
Infants weighing at least 1000 grams but less than 2000 grams represented 
54.89% of the ParadigmHealth dataset, 23.560/0 of the OSHPD dataset, and 
40.50/0 of the MillimanUSA dataset. Infants with birthweight of greater than 1999 
grams comprised 27.07% of the ParadigmHealth dataset, 73.040/0 of the OSHPD 
dataset, and 52.29% of the MillimanUSA dataset. 
Table 10 
Percentage Distribution of Cases by Birthweight 
Paradigm OSHPD Milliman 
SamQle % Distribution Health {CAl USA 
ECMO 1.13% 0.04% 0.080/0 
< 750G 6.02% 1.15% 2.54% 
750 - 999G 10.90% 2.22% 4.480/0 
1000 - 1499G 27.26% 7.33% 13.17% 
1500 - 1999G 27.630/0 16.230/0 27.43% 
2000 - 2499G 10.34% 19.34% 21.21% 
>2499G 16.730/0 53.700/0 31.080/0 
Total Sample Size 100.00% 100.00% 100.00% 
The proportion of infants within each of the datasets that would be 
considered very low birthweight (meaning < 1500 grams and ECMO categories) 
was largest within the ParadigmHealth dataset comprising 45.31 % of the sample 
while representing only 10.74% of the OSHPD dataset and 20.270/0 of the 
MillimanUSA dataset respectively. This higher proportion of very low birthweight 
infants in the ParadigmHealth dataset is expected given the sample is derived 
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from the firm's business model of managing fragile and catastrophic neonates. 
The relative proportion of infants across the various birthweight categories for the 
three datasets is shown in Figure 1. 





















ECMO < 750 G 750 - 999G 1000 - 1499G 1500 -1999G 2000 - 2499G >2499G 
EJ Paradigm Health 1. 13% 6.02% 10.90% 27.26% 27.63% 10.34% 16.73% 
.OSHPD 0.04% 1.15% 2.22% 7.33% 16.23% 19.34% 53.70% 
o MillimanUSA 0.08% 2.54% 4.48% 13.17% 27.43% 21.21% 31.08% 
Birthweight Category 
Figure 1: Sample Distribution by Birlhweight: ParadigmHealth, OSHPD, and 
MillimanUSA Datasets 
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The first analysis completed for each APR-DRG was the F-test to determine 
if the variances between the two data sets for that APR-DRG are equal. If the F-
test has a significant p-value (p < .05), then the Satterthwaite test (for unequal 
variances) was used to determine if the variance between the two means of the 
APR-DRG group was significant. If the F-test results in a p-value > .05, then the 
pooled t-test (for equal valiances) was used to determine if the variance between 
the two means of the APR-DRG group was significant. 
Using the t-test methodology, if the p-value is > or = to .05, then it is likely 
that the variances are not statistically significant to support a conclusion of 
unequal variance in t-test. If, however the p-value is < .05, then it is likely that 
the variances are unequal between the samples and the differences in mean 
values are significant. The t-test procedure was completed, comparing the mean 
of ParadigmHealth dataset to the mean of the MillimanUSA dataset and the 
mean of the OSHPD dataset. This tesf was first done as an overall comparison 
of the ALOS (matched using the DRG patient classification system) then by 
birthweight Tiers (1000 gram increments), and finally by individual APR-DRG. 
Overall Comparison: ParadigmHealth to MillimanUSA 
The initial t-test procedure compared the means of the ParadigmHealth 
dataset and the MillimanUSA dataset grouped by DRG. The results of the t-test 
revealed that the ALOS of the ParadigmHealth dataset was 5.59 days, on 
average, lower than the MillimanUSA ALOS for DRG-matched neonates (t = 
4.28, P < 0.0001). The mean differences between the ALOS reductions of the 
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ParadigmHealth and MillimanUSA samples ranged from 0 to 26 days (See 
Figure 2). The greatest differences were in the extremely low birthweight group 
« 1000 grams). 
Difference in ALOS: ParadigmHealth & MillimanUSA 
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1000 - 1500 - 2000 - > 2500 
1499 1999 2499 grams 
flALOS Diff 25.8 10.12 6.33 0.94 2 -0.17 9.09 
Figure 2: Paradigm ALOS Difference from MillimanUSA by Birthweight 
Comparison of Datasets by Birthweight Groups (Tiers) 
The researcher then grouped the APR-DRGs into groupings or Tiers (See 
Appendix C for definition and specific APR-DRG assignments to Tiers). Tier 1 is 
comprised of those infants with birth weights of 2000 grams and greater (APR-
DRGs 620 -640, severity levels 1 ,2, and 3). Tier 2 is comprised of those infants 
with birth weights that range from 1000 grams to 1999 grams (APR-DRGs 610-
614, severity levels 1,2, and 3; and APR-DRGs 600-603, severity levels 1 and 2). 
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Tier 3 is comprised of those infants weighing < 1000 grams (APR-DRGs 590-
593, severity levels 1 ,2,3, and 4). Tier 4 is comprised of the highest severity 
levels across all the various birthweight categories. It contains severity level four 
(4) cases for APR-DRGs 610-640; APR-DRGs 600-603, severity levels 3 and 4; 
and the entire ECMO and Organ Transplantation APR-DRG categories. 
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ParadigmHealth to MillimanUSA analysis - tier 1. For Tier 1 , the mean 
ALOS of the ParadigmHealth dataset was 12.676 days, 3.6127 days less than 
the mean ALOS for the MillimanUSA dataset (16.288 days). The F-test resulted 
in a p-value of < 0.0001 and the resulting Satterthwaite t-test for unequal 
variances yielded a p-value of 0.2990, thus the difference in the two means is not 
statistically significant (See Table 11). 
Table 11 






















LowerCL Upper CL Lower CL 
Mean Mean Mean Std Dev 
15.75 16.288 16.827 
5.8248 12.676 19.527 
-13.72 3.6127 20.95 83.496 











Equality of Variances 
t Value Pr > I t I 
0.41 0.683 
1.04 0.299 
Num OF Den OF F Value Pr> F 
93193 89 6.58 < .0001 
UpperCL 





ParadigmHealth to MillimanUSA analysis - tier 2. For Tier 2, the mean 
ALOS of the ParadigmHealth dataset was 24.103 days, 3.25 days less than the 
mean ALOS for the MillimanUSA dataset (27.361 days). The F-test resulted in a 
p-value of < 0.0001 and the resulting Satterthwaite t-test for unequal variances 
yielded a p-value of 0.2037, thus the difference in the two means is not 
statistically significant (See Table 12). 
Table 12 






















Lower CL Upper CL Lower CL 
Mean Mean Mean Std Dev 
26.729 27.361 27.994 
19.098 24.103 29.108 
-7.921 3.258 14.437 66.208 











Equality of Variances 
t Value Pr > I t I 
0.57 0.5678 
1.28 0.2037 
Num DF Den DF F Value Pr > F 









ParadigmHealth to MillimanUSA analysis - tier 3. For Tier 3, the mean 
ALOS of the ParadigmHealth dataset was 88.102 days, 7.64 days less than the 
mean ALOS for the MillimanUSA dataset (95.742 days). The F-test resulted in a 
p-value of < 0.0001 and the resulting Satterthwaite t-test for unequal variances 
yielded a p-value of 0.2213, thus the difference in the two means is not 
statistically significant (See Table 13). 
Table 13 
Tier 3: ParadigmHealth to MillimanUSA: ALOS Comparison 





















Lower CL Upper CL Lower CL 
Mean Mean Mean Std Dev 
92.919 95.742 98.565 
76.105 88.102 100.1 
-21.8 7.64 37.084 139.9 











Equality of Variances 
t Value Pr > I t I 
0.51 0.611 
1.23 0.2213 
Num DF Den DF F Value Pr > F 









ParadigmHealth to MillimanUSA analysis - tier 4. For Tier 4, the mean 
ALOS of the ParadigmHealth dataset was 41.781 days, 0.1969 days less than 
the mean ALOS for the MillimanUSA dataset (41.978 days). The F-test resulted 
in a p-value of < 0.0001 and the resulting Satterthwaite t-test for unequal 
variances yielded a p-value of 0.9749, thus the difference in the two means is not 
statistically significant (See Table 14). 
Table 14 






















LowerCL Upper CL Lower CL 
Mean Mean Mean Std Dev 
39.704 41.978 44.252 
29.665 41.781 53.897 
-23.83 0.1969 24.22 177.33 











Equality of Variances 
Num OF Den DF 
23942 214 
t Value Pr > I t I 
0.02 0.9872 
0.03 0.9749 
F Value Pr> F 
3.97 < .0001 
Upper CL 





Summary of findings for tiered comparisons. In each of the four Tiers, the 
ParadigmHealth ALaS was found to be lower than the MillimanUSA ALOS. For 
Tier 1 , the ParadigmHealth ALaS was lower by 3.6 days (ParadigmHealth n = 
90). For Tier 2, the ParadigmHealth ALOS was lower by 3.3 days 
(ParadigmHealth n = 137). For Tier 3, the ParadigmHealth ALOS was lower by 
7.6 days, the largest difference of means within this Tier comparison 
(ParadigmHealth n = 90). For Tier 4, the ParadigmHealth ALaS was lower by 
0.2 days (ParadigmHealth n = 215). Yet, based upon the F-test and t-test 
findings, none of these differences in the two means could be shown to be 
statistically significant (p-values for the Satterthwaite t-test ranged from 0.2037 -
0.9749) 
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ParadigmHealth to OSHPD analysis - tier 1" For Tier 1, the mean ALOS 
of the ParadigmHealth dataset was 12.676 days, 0.0831 days less than the 
mean ALOS for the OSHPD dataset (12.759 days). The F-test resulted in a p-
value of < 0.0001 and the resulting Satterthwaite t-test for unequal variances 
yielded a p-value of 0.9445, thus the difference in the two means is not 
statistically significant (See Table 15). 
Table 15 






















LowerCL Upper CL Lower CL 
Mean Mean Mean Std Dev 
12.457 12.759 13.061 
10.329 12.676 15.022 
-4.307 0.0831 4.473 20.987 










Equality of Variances 
t Value Pr > I t I 
0.04 0.9704 
0.07 0.9445 
Num DF Den DF F Value Pr > F 









ParadigmHealth to OSHPD analysis - tier 2. For Tier 2, the mean ALOS of 
the ParadigmHealth dataset was 24.103 days, 1.5804 days less than the mean 
ALOS for the OSHPD dataset (25.684 days). The F-test resulted in a p-value of 
< 0.0001 and the resulting Satterthwaite t-test for unequal variances yielded a p-
value of 0.0594, thus the difference in the two means is significant (alpha of 0.06) 
but not to the 0.05 level set by the researcher (See Table 16). 
Table 16 






















Lower CL Upper CL Lower CL 
Mean Mean Mean Std Dev 
25.247 25.684 26.121 
22.518 24.103 25.689 
-0.79 1.5804 3.9511 13.621 











Equality of Variances 
t Value Pr > I t I 
1.31 0.1913 
1.90 0.0594 
Num OF Den OF F Value Pr> F 
3969 136 2.24 < .0001 
Upper CL 





ParadigmHealth to OSHPD analysis - tier 3. For Tier 3, the mean ALOS 
of the ParadigmHealth dataset was 88.102 days, 6.362 days greater than the 
mean ALOS for the OSHPD dataset (81.74 days). The F-test resulted in a p-
value of 0.0006 and the resulting Satterthwaite t-test for unequal variances 
yielded a p-value of < 0.0001, thus the difference in the two means is significant 
(See Table 17). 
Table 17 






















Lower CL Upper CL Lower CL 
Mean Mean Mean Std Dev 
80.682 81.74 82.799 
85.795 88.102 90.409 
~9.535 -6.362 ~3.189 13.843 











Equality of Variances 
t Value Pr > I t I 
-3.94 < .0001 
-0.04 < .0001 
Num OF Den OF F Value Pr > F 
758 89 1.82 < .0006 
Upper CL 





ParadigmHealth to OSHPD analysis - tier 4. For Tier 4, the mean ALOS 
of the ParadigmHealth dataset was 41.781 days, 7.116 days greater than the 
mean ALOS for the OSHPD dataset (34.665 days). The F-test resulted in a p-
value of 0.0026 and the resulting Satterthwaite t-test for unequal variances 
yielded a p-value of < 0.0001, thus the difference in the two means is significant 
(See Table 18). 
Table 18 


























Lower CL Upper CL Lower CL 
Mean Mean Mean Std Dev 
33.708 34.665 35.621 
39.12 41.781 44.443 
-10.33 -7.116 -3.901 22.258 











t Value Pr > I t I 
-4.34 < .0001 
-4.96 < .0001 
Equality of Variances 
Num OF Den DF F Value Pr > F 
2273 214 1.38 < .0026 
UpperCL 





Summary of findings for tiered comparisons. In the first two Tiers, the 
ParadigmHealth ALOS was found to be lower than the aSHPD ALaS. For Tier 
1 , the ParadigmHealth ALOS was lower by 0.08 days (ParadigmHealth n = 90). 
For Tier 2, the ParadigmHealth ALaS was lower by 1.58 days ParadigmHealth n 
= 137). Based upon the F-test and t-test findings, neither of these differences in 
the two means could be shown to be statistically significant. 
For Tier 3, the ParadigmHealth ALaS was higher than the aSHPD ALaS 
by 6.36 days, a significant difference of means within this Tier comparison 
(ParadigmHealth n = 90). For Tier 4, the ParadigmHealth ALaS was higher than 
the OSHPD ALaS by 7.12 days (ParadigmHealth n = 215). Based upon the F-
test and t-test findings, both of these differences in the two means were shown to 
be statistically significant (p-values for the Satterthwaite t-test were < 0.0001 in 
both Tier 3 and Tier 4). 
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OSHPD to MillimanUSA analysis - tier 1. For Tier 1, the mean ALOS of the 
OSHPD dataset was 12.759 days, 3.5297 days less than the mean ALOS for the 
MillimanUSA dataset (16.288 days). The F-test resulted in a p-value of < 0.0001 
and the resulting Satterthwaite t-test for unequal variances yielded a p-value of < 
0.0001 , thus the difference in the two means is significant (See Table 19). 
Table 19 






















LowerCL Upper CL Lower CL 
Mean Mean Mean Std Dev 
16.139 16.288 16.438 
12.457 12.759 13.061 
3.172 3.5297 3.8874 22.834 











Equality of Variances 
Num OF Den OF 
93193 19001 
t Value Pr > I t I 
19.34 < .0001 
20.54 < .0001 
F Value Pr> F 
1.2 < .0001 
UpperCL 





OSHPD to MillimanUSA analysis - tier 2. For Tier 2, the mean ALOS of the 
OSHPD dataset was 25.684 days, 1.6776 days less than the mean ALOS for the 
MillimanUSA dataset (27.361 days). The F-test resulted in a p-value of < 0.0001 
and the resulting Satterthwaite t-test for unequal variances yielded a p-value of < 
0.0001, thus the difference in the two means is significant (See Table 20). 
Table 20 


























LowerCL Upper CL Lower CL 
Mean Mean Mean Std Dev 
27.203 27.361 27.519 
25.247 25.684 26.121 
1.1425 1.6776 2.2128 16.35 











t Value Pr > I t I 
6.14 < .0001 
7.08 < .0001 
Equality of Variances 
Num OF Den DF F Value Pr > F 
42731 3969 1.41 < .0001 
Upper CL 





OSHPD to MillimanUSA analysis - tier 3. For Tier 3, the mean ALaS of 
the aSHPD dataset was 81.74 days, 14.002 days less than the mean ALaS for 
the MillimanUSA dataset (95.742 days). The F-test resulted in a p-value of < 
0.0001 and the resulting Satterthwaite t-test for unequal variances yielded a p-
value of < 0.0001, thus the difference in the two means is significant (See Table 
21 ). 
Table 21 






















Lower CL Upper CL Lower CL 
Mean Mean Mean Std Dev 
95.309 95.742 96.175 
80.682 81.74 82.799 
12.42 14.002 15.584 21.135 











Equality of Variances 
Num DF Den DF 
9776 758 
t Value Pr > I t I 
17.35 < .0001 
24.03 < .0001 
F Value Pr> F 
2.16 < .0001 
Upper CL 





OSHPD to MillimanUSA analysis - tier 4. For Tier 4, the mean ALaS of 
the aSHPD dataset was 34.665 days, 7.3134 days greater than the mean ALaS 
for the MillimanUSA dataset (41.978 days). The F-test resulted in a p-value of < 
0.0001 and the resulting Satterthwaite t-test for unequal variances yielded a p-
value of < 0.0001 , thus the difference in the two means is significant (See Table 
22). 
Table 22 






















LowerCL Upper CL Lower CL 
Mean Mean Mean Std Dev 
41.596 41.978 42.36 
33.708 34.665 35.621 
6.0399 7.3134 8.5868 29.356 











Equality of Variances 
t Value Pr > I t I 
11.26 < .0001 
13.93 < .0001 
Num DF Den DF F Value Pr > F 
23942 2273 1.68 < .0001 
Upper CL 





Summary of findings for tiered comparisons. In each of the four Tiers, the 
OSHPD ALOS was found to be lower than the MillimanUSA ALOS. For Tier 1, 
the OSHPD ALOS was lower by 3.52 days (OSHPD n = 19,002). For Tier 2, the 
OSHPD ALOS was lower by 1.67 days (OSHPD n = 3,970). For Tier 3, the 
OSHPD ALOS was lower by 14.002 days, the largest difference of means within 
this Tier comparison (OSHPD n = 759). For Tier 4, the OSHPD ALOS was lower 
by 7.31 days (OSHPD n = 2,274). Based upon the F-test and t-test findings, the 
differences in the two means was statistically significant (all p-values for the 
Satterthwaite t-test were < 0.0001) in all four Tiers. 
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Aggregate tier analysis. The ALaS of the ParadigmHealth dataset is 
lower than the ALaS of the MillimanUSA dataset across all four Tiers. The ALaS 
of the ParadigmHealth dataset is also lower than the ALaS for the aSHPD 
dataset for Tier 1 and Tier 2. The reverse is true for Tier 3 and Tier 4 in which 
the aSHPD ALaS is lower. The ALaS of the aSHDP dataset is lower than the 
































None of the Tier comparisons between ParadigmHealth and MillimanUSA 
were shown to be statistically significant. In comparing the Tier groups of the 
aSHPD dataset and the ParadigmHealth dataset, the differences in mean ALaS , 
for Tiers 3 and 4 are statistically significant. In comparing the Tier groups of the 
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OSHPD dataset and the MillimanUSA dataset, the differences in mean ALOS for 
all four Tiers are statistically significant. Using the ParadigmHealth ALOS as the 
baseline, Figure 4 presents the relative comparison of the mean ALOS for each 
of the three datasets. 
Tiered T -test (Paradigm Base) 
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Figure 4: ALOS Difference: ParadigmHealth as Baseline 
Comparison of the ParadigmHealth and MillimanUSA Datasets by APR-DRG 
There were 82 APR-DRG categories within which both the ParadigmHealth 
dataset and the MillimanUSA dataset had neonatal cases. Of these, 20 
categories had only one ParadigmHealth observation. While they were included 
in the overall study for grouping purposes, those individual APR-DRGs were not 
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compared. The remaining 62 APR-DRG categories were individually compared 
and grouped by DRG birthweight categories. Following the t-test procedure, 
twelve APR-DRGs appeared to have significant differences of the two means 
and are reported in Table 23. 
Table 23 
Comparison of ParadigmHealth & MillimanUSA by APR-DRG 
APR-DRG Parad igm Health MillimanUSA Difference ~-value Paradigm n Milliman n 
593/3 64.83 76.43 (11.60) 0.0248 12 1,219 
601/4 38.00 59.45 (21.45) 0.0336 4 853 
610/4 40.25 69.01 (28.76) 0.0150 4 297 
612/1 32.00 18.55 13.45 0.0249 2 1,133 
614/1 15.85 12.97 2.88 0.0164 27 10,842 
622.1 10.00 10.72 (0.72) 0.0001 2 1,527 
626/2 8.00 15.20 (7.20) 0.0006 4 1,191 
626/3 9.33 16.25 (6.92) 0.0009 6 2,037 
630/4 27.90 49.93 (22.03) 0.0023 10 600 
634/4 19.40 37.61 (18.21) 0.0030 5 2,104 
635/3 10.00 11.78 (1.78) 0.0001 2 1,995 
639/3 15.00 25.95 {10.95} 0.0355 8 989 
Of these twelve APR-DRGs, all were ruled as inconclusive tests due to relatively 
small ParadigmHealth sample size (n < 25) except for APR-DRG 614, severity 
level 1. For this APR-DRG, the mean ALOS of the ParadigmHealth dataset was 
15.852 days, 2.884 days greater than the mean ALOS for the MillimanUSA 
dataset (12.968 days). 
Comparison of the ParadigmHealth and OSHPD Datasets by APR-DRG 
There were 81 APR-DRG categories within which both the ParadigmHealth 
dataset and the OSHPD dataset had neonatal cases. Of these, 33 categories 
had only one ParadigmHealth observation. While they were included in the 
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overall study for grouping purposes, those individual APR-DRGs were not 
compared. The remaining 48 APR-DRG categories were individually compared 
and grouped by DRG birthweight categories. Following the t-test procedure, 
eight (8) APR-DRGs appeared to have significant differences of the two means 
are reported in Table 24. 
Table 24 
Comparison of ParadigmHealth & OSHPD by APR-DRG 
APR-DRG Paradigm Health OSHPD Difference ~-value Paradigm n Milliman n 
60114 38.00 60.22 (22.22) 0.0415 4 106 
611/3 23.67 31.03 (7.37) 0.0078 3 93 
614/1 15.85 13.40 2.45 0.0451 27 1,055 
622/1 10.00 11.11 (1.11 ) 0.0047 2 158 
635/3 10.00 8.94 1.06 0.0008 2 264 
639/2 17.00 8.56 8.44 0.0036 3 1,221 
639/4 30.00 17.03 12.98 0.0468 3 40 
640/3 13.00 6.94 6.06 0.0030 3 1,457 
Of the eight, all were ruled as inconclusive due to relatively small 
ParadigmHealth sample size (n < 25) except for APR-DRG 614, severity level 1. 
For APR-DRG 614, severity level 1, the mean ALOS of the ParadigmHealth 
dataset was 15.852 days, 2.451 days greater than the mean ALOS for the 
OSHPD dataset (13.401 days). 
Analysis of Range of Length ~f Stay 
An analysis was performed of the ParadigmHealth, OSHPD, and 
MillimanUSA datasets to evaluate the range of length of stay represented in each 
of the birthweight groups. For each of the birthweight groups, the lowest LOS 
and the Highest LOS was recorded. These findings are shown in Table 25. 
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Analysis of length of stay range for infants with ECMO procedures. For 
the ECMO Category, the ParadigmHealth total LOS range was 45 days, lower 
than the range for both the MillimanUSA dataset (367 days) and the OSHPD 
dataset (53 days). Both the MillimanUSA and the OSHPD datasets had cases 
with shorter LOS with the minimum LOS point being in the MillimanUSA dataset 
(6 days). The OSHPD dataset's maximum LOS point was the lowest (53 days) 
and the MillimanUSA dataset's maximum LOS point was the greatest (373 days). 
Analysis of length of stay range for infants with birlhweight < 750 grams. 
Within this category, the ParadigmHealth total LOS range was 115 days, lower 
than the range for both the MillimanUSA dataset (832 days) and the OSHPD 
dataset (229 days). Both the MillimanUSA and the OSHPD datasets had cases 
with shorter LOS with the minimum LOS point being in the OSHPD dataset (11 
days). The ParadigmHealth dataset's maximum LOS point was the lowest (180 
days) and the MillimanUSA dataset's maximum LOS point was the greatest (884 
days). 
Analysis of length of stay range for infants with birlhweight 750 - 999 
grams. Within this category, the ParadigmHealth total LOS range was 170 days, 
lower than the range for both the MillimanUSA dataset (334 days) and the 
OSHPD dataset (380 days). The OSHPD dataset had cases with shorter LOS 
with the minimum LOS paint being 6 days. The ParadigmHealth dataset's 
maximum LOS point was the lowest (206 days) and the OSHPD dataset's 
maximum LOS point was the greatest (386 days). 
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Analysis of length of stay range for infants with birthweight 1000 - 1499 
grams. Within this category, the ParadigmHealth total LOS range was 144 days, 
lower than the range for both the MillimanUSA dataset (337 days) and the 
OSHPD dataset (271 days). The OSHPD dataset had cases with shorter LOS 
with the minimum LOS point being 5 days. The ParadigmHealth dataset's 
maximum LOS point was the lowest (160 days) and the MillimanUSA dataset's 
maximum LOS point was the greatest (354 days). 
Analysis of length of stay range for infants with birth weight 1500 - 1999 
grams. Within this category, the ParadigmHealth total LOS range was 65 days, 
lower than the range for both the MillimanUSA dataset (560 days) and the 
OSHPD dataset (187 days). The ParadigmHealth dataset had cases with shorter 
LOS with the minimum LOS point being 4 days. The ParadigmHealth dataset's 
maximum LOS point was also the lowest (69 days) and the MillimanUSA 
dataset's maximum LOS point was the greatest (565 days). 
Analysis of length of stay range for infants with birthweight 2000 - 2499 
grams. Within this category, the ParadigmHealth total LOS range was 103 days, 
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lower than the range for both the MillimanUSA dataset (468 days) and the 
OSHPD dataset (198 days). The ParadigmHealth dataset had cases with shorter 
LOS with the minimum LOS point being 3 days. The ParadigmHealth dataset's 
maximum LOS point was also the lowest (206 days) and the MillimanUSA 
dataset's maximum LOS point was the greatest (473 days). 
Analysis of length of stay range for infants with birthweight > 2499 grams. 
Within this category, the ParadigmHealth total LOS range was 130 days, lower 
than the range for both the MillimanUSA dataset (508 days) and the OSHPD 
dataset (159 days). Both the ParadigmHealth dataset and the OSHPD dataset 
had cases with shortest LOS with the minimum LOS point being 5 days for each. 
The ParadigmHealth dataset's maximum LOS point was also the lowest (135 




Comparison of LOS Ranges within Birlhweight Groups 
Birthweight Category Low LOS High LOS Range Dataset 
ECMO 34 79 45 Paradigm 
6 373 367 Milliman 
13 66 53 OSHPD 
<750G 65 180 115 Paradigm 
52 884 832 Milliman 
11 240 229 OSHPD 
750 - 999G 36 206 170 Paradigm 
38 372 334 Milliman 
6 386 380 OSHPD 
1000-1499G 16 160 144 Paradigm 
17 354 337 Milliman 
5 276 271 OSHPD 
1500-1999G 4 69 65 Paradigm 
5 565 560 Milliman 
5 192 187 OSHPD 
2000-2499G 3 106 103 Paradigm 
5 473 468 Milliman 
5 203 198 OSHPD 
>2499G 5 135 130 Paradigm 
6 514 508 Milliman 
5 164 159 OSHPD 
Summary of findings. For each of the birthweight categories, the 
ParadigmHealth dataset showed the smallest range in total length of stay. With 
the exception of the ECMO category, the ParadigmHealth dataset also yielded 
the lowest maximum length of stay point across the birthweight categories. 
Within the ECMO category, the OSHPD dataset yielded the lowest maximum 
length of stay point. A graphical display of these lengths of stay ranges is 























Figure 5: Total Length of Stay Range by Birthweight Category 
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v. Discussion 
There are numerous ideological and operational challenges involved in 
attempting to impact the average length of stay for NICUs. In today's era of cost 
containment and accountability for quality of care, any connection between 
experience and patient outcome has far reaching implications for patients, 
payers, and governmental agencies. Despite compelling evidence of the value of 
highly specialized neonatal intensive care units, questions remain about the 
proliferation of these units and the clinical processes that determine length of 
stay (Doyle et aI., 1988; McLean et aI., 2002). 
The objective of this study was to determine the effectiveness of 
Paradigm Health's systematic care management (SCM) model in reducing both 
the average length of stay (ALOS) for NICU cases and the range in NICU lengths 
of stay. The initial test, a t-test of the overall datasets linked by DRG, revealed 
that the ALOS of the ParadigmHealth dataset was 5.56 days lower than the 
MillimanUSA dataset and was found to be statistically significant. When broken 
into individual APR-DRGs, the ALaS for the ParadigmHealth dataset was below 
the ALOS of either comparison group for the majority of the APR-DRGs. This 
level of analysis resulted in very small sample sizes for each APR-DRG for the 
ParadigmHealth dataset and the majority of the tests, while clearly showing a 
lower ALaS for the ParadigmHealth dataset, were deemed inconclusive. One 
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APR-DRG cell had a sufficient size to show statistical significance (the same cell 
for both the MillimanUSA and OSHPD). Interestingly, this was a low severity 
(severity 1) "other" category for a relatively large neonate (1500 - 1999 grams). 
Within the birthweight Tier analysis (1000 gram increments), the ParadigmHealth 
dataset revealed lower ALOS than the MillimanUSA dataset in all four Tiers. The 
ParadigmHealth dataset showed lower ALOS than the OSHPD dataset for Tiers 
1 and 2 but greater ALOS than the OSHPD dataset for Tiers 3 and 4. Only Tiers 
3 and 4 of the ParadigmHealth to OSHPD comparison showed statistical 
significance. 
Perhaps the most revealing part of the study was the range of LOS 
analyses. In all categories, the ParadigmHealth dataset revealed a lower range 
of LOS than either the MillimanUSA dataset or the OSHPD dataset. 
Interestingly, the ParadigmHealth dataset contains the greatest proportion of Tier 
4 cases - the most medically complex neonates. 
The researcher acknowledges that these findings are inconclusive when 
one focuses only on the individual statistical tests. However, in looking at the 
analyses in total, one can find clear evidence that the SCM approach indeed 
reduces the range of length of stay for neonates. One can draw tentative 
conclusions regarding the effectiveness of the SCM approach in reducing 
average length of stay. The results are discussed in more detail below. 
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Tests for Significance: Overall Comparison of ParadigmHealth to MillimanUSA 
The first t-test procedure compared the means of the paradigmHealth 
dataset and the MillimanUSA dataset grouped by DRG. The results of the t-test 
revealed that the ALaS of the ParadigmHealth dataset was 5.59 days, on 
average, lower than the MillimanUSA ALOS for DRG-matched neonates (t = 
4.28, P < 0.0001). The mean differences between the ALOS reductions of the 
ParadigmHealth and MillimanUSA samples ranged from 0 to 26 days with 
greatest differences were in the extremely low birthweight group (those infants < 
1000 grams) as shown in Figure 2. Interestingly, the difference in average length 
of stay between the ParadigmHealth dataset and the MillimanUSA dataset 
declines as birthweight increases until the final category (infants> 2500 grams). 
These cases are primarily infants with seemingly normal birth weights but having 
any number of congenital anomalies or other clinical complexities that cause an 
admission to the NICU. In this area, ParadigmHealth's ALaS is well below the 
MillimanUSA ALaS, similar to its performance with the lower birthweight infants. 
Tests for Significance: Individual APR-DRG Comparisons 
Following the overall comparison, additional t-test procedures were 
completed comparing, by individual APR-DRG the mean of ParadigmHealth 
dataset to the mean of the MillimanUSA dataset and the mean of the OSHPD 
dataset. Given that this test was done by individual APR-DRG, it is not surprising 
that the ParadigmHealth sample sizes for each become quite small (the total n 
for ParadigmHealth is 532 and there are 132 APR-DRG categories). The 
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purpose of this additional analysis was to both identify any trend that might exist 
in discreet APR-DRGs and to further test for differences in the means that may 
be shown to be significant. 
ParadigmHealth and MillimanUSA analysis. There were 82 APR-DRG 
categories within which both the ParadigmHealth dataset and the MillimanUSA 
dataset had neonatal cases. Of these, 20 categories had only one 
ParadigmHealth observation. While they were included in the overall study for 
grouping purposes, those individual APR-DRGs were not compared. The 
remaining 62 APR-DRG categories were individually compared. In 47 of the 62 
APR-DRG categories, the ParadigmHealth ALOS was less than the MillimanUSA 
ALaS. Following the t-test procedure, twelve APR-DRGs appeared to have 
significant differences. All were ruled as inconclusive due to relatively small 
ParadigmHealth sample size (n < 25) except for APR-DRG 614, severity level 1. 
For this APR-ORG, the mean ALOS of the ParadigmHealth dataset was 15.852 
days, 2.884 days greater than the mean ALaS for the MillimanUSA dataset 
(12.968 days). 
APR-DRG 614-1 is considered an "other" category of low severity 
(severity 1). To score a severity 1 the birthweight is matched with only one 
diagnostic or procedure code (indicating the absence of co-morbidities). In the 
researcher's view, ParadigmHealth's caseload is more oriented to higher severity 
infants and, even within such refined categories as the APR-DRG classification 
system, differences in severity exist. It appears to be a bit of a'n aberration, in the 
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researcher's view, that the "other" category is the one in which ParadigmHealth's 
ALOS was higher and not within the categories in which a co-morbidity, 
congenital anomaly or other clinical complexity is actually defined. 
ParadigmHealth and OSHPD analysis. There were 81 APR-DRG 
categories within which both the ParadigmHealth dataset and the OSHPD 
dataset had neonatal cases. Of these, 33 categories had only one 
ParadigmHealth observation. While they were included in the overall study for 
grouping purposes, those individual APR-DRGs were not compared. The 
remaining 48 APR-DRG categories were individually compared. In 32 of the 48 
APR-DRG categories, the ParadigmHealth ALOS was less than the OSHPD 
ALOS. Following the t-test procedure, eight APR-DRGs appeared to have 
significant differences. All were ruled as inconclusive due to relatively small 
ParadigmHealth sample size (n < 25) except for APR-DRG 614, severity level 1. 
For APR-DRG 614, severity level 1, the mean ALOS of the ParadigmHealth 
dataset was 15.852 days, 2.451 days greater than the mean ALOS for the 
OSHPD dataset (13.401 days). 
Oddly, the same APR-DRG was identified in the ParadigmHealth and 
MillimanUSA comparison. In both instances, the ParadigmHealth ALOS is higher 
than the comparison sample. This finding, in the researcher's view, lends 
additional credibility to the logic given for this same difference in the 
ParadigmHealth and MillimanUSA comparison. 
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Tests for Significance: Tier Group Comparisons 
The researcher then grouped the APR-DRGs into birthweight Tiers. (See 
Appendix C for definition and specific APR-DRG assignments to Tiers.) There is 
a relatively large difference in the proportion of cases for Tiers 3 and 4 within the 
ParadigmHealth dataset in contrast to both comparison samples. Tier 3 includes 
all infants weighing less than 1000 grams. This Tier represents 150/0 of the 
ParadigmHealth dataset while comprising only 3% of the OSHPD dataset and 
60/0 of the MillimanUSA dataset. Tier 4 includes the most medically complex 
categories of infants (severity 4 and ECMO). Tier 4 represents 420/0 of the 
ParadigmHealth dataset while comprising only 12% of the OSHPD dataset and 
16% of the MillimanUSA dataset. These proportional findings, in the 
researcher's view, validate the assertion made by ParadigmHealth the cases 
managed by the SCM team tend to be the most medically complex neonates. 
ParadigmHealth and MillimanUSA analysis. In each of the four Tiers, the 
ParadigmHealth ALOS was found to be lower than the ALOS for the 
MillimanUSA dataset. The findings of this analysis are consistent with the overall 
comparison of the ParadigmHealth dataset and the MillimanUSA dataset. These 
findings are consistent with the lower ALOS found within the ParadigmHealth 
dataset across the majority of the APR-DRGs compared. Based upon the F-test 
and t-test findings, these differences in the Tier group means could not be shown 
to be statistically significant (p-values for the Satterthwaite t-test ranged from 
0.2037 - 0.9749). 
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ParadigmHealth and OSHPD analysis. In the first two Tiers, the 
ParadigmHealth ALOS was found to be lower than the OSHPD ALOS. Based 
upon the F-test and t-test findings, neither of these differences in the two means 
could be shown to be statistically significant For Tier 3, the ParadigmHealth 
ALOS was higher than the OSHPD ALOS by 6.36 days (ParadigmHealth n = 90). 
For Tier 4, the ParadigmHealth ALOS was higher than the OSHPD ALOS by 
7.12 days (ParadigmHealth n = 215). Based upon the F-test and t-test findings, 
both of these differences in the two means were shown to be statistically 
significant (p-values for the Satterthwaite t-test were < 0.0001 in both Tier 3 and 
Tier 4). Interestingly, the OSHPD dataset had the lowest proportion of extremely 
low birthweight (infants < 1000 grams, Tier 3) and the lowest proportion of 
severity 4 cases (only 12% of the OSHPD Dataset). These proportional 
differences, in the researcher's view, largely explain the findings of the analysis 
for Tier 3 and Tier 4. Another observation is that the OSHPD dataset is solely a 
California dataset, a market known for much more aggressive case management 
by health insurers and for having a greater supply of NICUs per capita that the 
rest of the nation (Thompson et aI., 2002). 
OSHPD and MillimanUSA analysis. In each of the four Tiers, the OSHPD 
ALOS was found to be lower than the MillimanUSA ALOS. Based upon the F-
test and t-test findings, the differences in the two means was statistically 
significant (all p-values for the Satterthwaite t-test were < 0.0001) in all four Tiers. 
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Summary of findings. The ALOS of the ParadigmHealth dataset is lower 
than the ALOS of the MillimanUSA dataset across all four Tiers. The ALOS of the 
ParadigmHealth dataset is lower than the ALOS for the OSHPD dataset for Tier 
1 and Tier 2. The reverse is true for Tier 3 and Tier 4 in which the OSHPD ALOS 
is lower. The ALOS of the OSHDP dataset is lower than the ALOS of the 
MillimanUSA dataset across all four Tiers. None of the Tier comparisons 
between ParadigmHealth and MillimanUSA were shown to be statistically 
significant. In comparing the Tier groups of the OSHPD dataset and the 
ParadigmHealth dataset, the differences in mean ALOS for Tiers 3 and 4 are 
statistically significant. In comparing the Tier groups of the OSHPD dataset and 
the MillimanUSA dataset, the differences in mean ALOS for all four Tiers are 
statistically significant. 
Range of LOS Analysis 
Table 25 reflects the findings of the researcher in comparing the range of 
length of stay (LOS) between the ParadigmHealth dataset and the two 
comparison samples. These findings are, perhaps, the most revealing of the 
entire study. The APR-DRGs representing the smaller birthweight groups 
demonstrate greater spread in the range of LOS than those representing the 
larger birthweight groups. 
For each of the birthweight categories, the ParadigmHealth dataset 
demonstrated the lowest range in total length of stay. With the exception of the 
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ECMO category, the ParadigmHealth dataset yielded the lowest maximum length 
of stay point across the birthweight categories. Within the ECMO category, the 
OSHPD dataset yielded the lowest maximum length of stay point. The predictive 
modeling tools used by ParadigmHealth to quantify neonatal risk factors, 
establish and predict the probability of complications, and the management tools 
used to mitigate these risks may well be the drivers for this significant difference 
in the range of LOS. Clearly, this is an area that warrants further study. 
Table 26 
Range of Variability in Total LOS: ParadigmHealth, OSHPD, and MillimanUSA 
Birthweight Category Low LOS High LOS Range Dataset 
ECMO 34 79 45 Paradigm 
6 373 367 Milliman 
13 66 53 OSHPD 
<750G 65 180 115 Paradigm 
52 884 832 Milliman 
11 240 229 OSHPD 
750 - 999G 36 206 170 Paradigm 
38 372 334 Milliman 
6 386 380 OSHPD 
1000-1499G 16 160 144 Paradigm 
17 354 337 Milliman 
5 276 271 OSHPD 
1500-1999G 4 69 65 Paradigm 
5 565 560 Milliman 
5 192 187 OSHPD 
2000-2499G 3 106 103 Paradigm 
5 473 468 Milliman 
5 203 198 OSHPD 
>2499G 5 135 130 Paradigm 
6 514 508 Milliman 
5 164 159 OSHPD 
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Readmission Following NICU Discharge 
A concern may be raised that the achievement of ALOS reductions could 
be detrimental to the clinical quality of the outcomes. This could be evidenced by 
efficient discharges, but a higher than predicted number of readmissions. 
ParadigmHealth's outcome-based management process includes ongoing 
management for a minimum of 30 days after discharge from the NICU and if a 
readmission occurs, ParadigmHealth has a financial responsibility for that re-
hospitalization. To confirm that ParadigmHealth achieved its reduction in LOS 
without sacrificing quality through re-hospitalizations, a comparison was made of 
the incidence of re-hospitalizations within the first 30 days post discharge from 
the NICU between ParadigmHealth and an APR-DRG matched sample. 
As the MillimanUSA database did not include post-discharge follow-up at 
30 days, an alternative comparison sample was obtained from the OSHPD 
database managed by Dr. Phibbs at the Stanford office of the National Bureau of 
Economic Research. The results of the comparison of the severity-matched 
groups revealed that there was no difference in the rate of re-admissions 
between the two groups. The percentage of re-admissions was 60/0 percent for 
both groups. While there were no differences in the rate of readmissions, the 
average LOS of the Paradigm readmissions was 1.6 days shorter than the 
comparison sample. This may be due to the fact that ParadigmHealth was also 
accountable for the management of the readmission as well. 
104 
Pro forma Calculation of Hospital Charges 
A pro forma calculation of the reduced hospital charges associated with a 
reduction in ALaS, using MillimanUSA national data, indicates an average 
reduction of between $15,306 and $24,222. This reduction in particular is 
dramatic for the most complex of the neonates, those under 750 grams 
birthweight, who show a LOS reduction of 8 days with pro-forma savings of 
approximately $36,790. Such reductions are relevant to the payer (not the 
provider) as they represent reductions in facility charges corresponding to a 
reduction in NICU patient LOS and do not necessarily reflect a reduction in 
provider cost for the episode of care. 
Conclusions 
Following the specific aims identified in chapters 1 and 3, there were two 
significant findings identified in this research project and supported by the data 
presented in Chapter Four: 
1. To determine whether the SCM process of management is associated 
with significant reductions in the average length of stay (ALOS) of 
complex, high-risk neonates during their initial NICU hospitalization. 
The researcher acknowledges that these findings are inconclusive when one 
focuses only on the individual statistical tests. However, in looking at the 
analyses in total, one can draw tentative conclusions regarding the effectiveness 
of the SCM approach in reducing average length of stay. The overall 
comparison of the ParadigmHealth dataset and the MillimanUSA dataset 
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revealed that ParadigmHealth's ALOS was 5.56 days lower. While the more 
refined tests were largely inconclusive due to small sample sizes within a single 
APR-DRG, the ParadigmHealth dataset yielded lower ALOS for the majority of 
the APR-DRGs tested. 
2. To determine whether SCM is effective in reducing the range of NICU 
lengths of stay. 
Across all birthweight categories, the ParadigmHealth dataset showed the least 
range in total length of stay (defined as maximum LOS - minimum LOS). With 
the exception of one category, ECMO, the ParadigmHealth dataset also yielded 
the lowest maximum length of stay point across the birthweight categories. 
Within the ECMO category, the OSHPD dataset yielded the lowest maximum 
length of stay point. In the researcher's view, this is a highly relevant finding and 
an area for additional study as a number of predictive modeling tools are used 
within the SCM process to predict and mitigate potential problems and risks. 
Research Question Revisited 
In comparing the ParadigmHealth dataset to the MillimanUSA dataset, the 
research presented here provides support to reject the H1 research hypotheses 
presented in chapters 1 and 3. The overall comparison of the ParadigmHealth 
and MillimanUSA datasets yielded a 5.56 day lower ALOS for the 
ParadigmHealth dataset. Yet while all the Tier groups resulted in a lower ALOS 
for the ParadigmHealth dataset, the findings could not be shown to be 
statistically significant. This finding was repeated within the individual APR-DRG 
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comparisons in which, for a majority of the cases, a lower ALOS was found for 
the ParadigmHealth dataset but the relatively small sample size prohibited the 
comparison from achieving statistical significance. Accordingly, the researcher 
has rejected the research hypothesis and accepted the corresponding null 
hypotheses presented based on the following findings: 
H 1 : There is no evidence that ParadigmHealth's Systematic Care 
Management (SCM) process results in a reduction in ALOS (and 
therefore, the null hypothesis is accepted). 
In comparing the ParadigmHealth dataset to the MillimanUSA dataset, the 
research presented here provides support to accept the H2 research hypotheses 
presented in chapters 1 and 3. Accordingly, the researcher has rejected the null 
hypothesis presented based on the following findings: 
H2: There is evidence that the SCM process reduces the range of 
patient length of stay in the high-risk neonate (NICU) population 
(and therefore the null hypothesis is rejected). 
In comparing the ParadigmHealth dataset to the OSHPD dataset, the 
research presented here provides no support to accept the H1 research 
hypotheses presented in chapters 1 and 3. Two Tier groups resulted in a higher 
ALOS for the ParadigmHealth dataset; the differences of which were statistically 
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significant. While Tier groups 1 and 2 resulted in a lower ALaS for the 
ParadigmHealth dataset, the findings could not be shown to be statistically 
significant. This finding was repeated within the individual APR-DRG 
comparisons in which, for a majority of the cases, a lower ALaS was found for 
the ParadigmHealth dataset but the relatively small sample size prohibited the 
comparison from achieving statistical significance. Accordingly, the researcher 
has rejected the research hypothesis and accepted the corresponding null 
hypotheses presented based on the following findings: 
H1: There is no evidence that ParadigmHealth's Systematic Care 
Management (SCM) process results in a reduction in ALaS (and 
therefore, the null hypothesis is accepted). 
In comparing the ParadigmHealth dataset to the aSHPD dataset, the 
research presented here provides support to accept the H2 research hypotheses 
presented in chapters 1 and 3. Accordingly, the researcher has rejected the null 
hypothesis presented based on the following findings: 
H2: There is evidence that the SCM process reduces the range of 
patient length of stay in the high-risk neonate (NICU) population 
(and therefore the null hypothesis is rejected). 
108 
Implications for NICU Management 
The results of this study are largely inconclusive as to whether the 
application of ParadigmHealth's Systematic Care Management (SCM) model 
(Bryant, 2002; Gardner, 1999) is associated with reductions in NICU lengths of 
stay for severity-matched neonates. The overall comparison of the 
ParadigmHealth dataset and the MillimanUSA dataset revealed a 5.56 day lower 
ALOS for the ParadigmHealth dataset (t = 4.28, P < .0001). Within the individual 
APR-DRG groups, the relatively small numbers of infants allow only tentative 
conclusions. Given that a majority of the cases reviewed showed a lower ALaS 
for the ParadigmHealth dataset, additional cases may provide more conclusive 
evidence in the future. 
Perhaps the most significant finding was the marked reduction in the 
range of LOS within the ParadigmHealth dataset. The SCM process includes 
predictive modeling tools used by ParadigmHealth to quantify neonatal risk 
factors to establish and predict the risk and probability of neonatal complications. 
In addition the SCM process provides both clinical- and data-oriented 
management tools used to mitigate these risks. These aspects of the SCM 
model may well be the drivers for this significant difference in the range of LOS. 
This is an area that warrants further study. 
The strength of the findings is supported by the wide geographic spread of 
the population of infants studied, which represents most regions of the 
continental United States, as well as the extended three-year period over which 
the data were gathered. The results are strengthened when contrasted with 
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general experience of increasing average lengths of stay (ALOS) as the number 
and survival of very low birthweight infants continues to increase. 
From the view of the health care payer (or purchaser) a reduction in ALOS 
may result in a reduction in total costs incurred for the NICU experience 
(Gardner, 1999; McLean et aI., 2002). The exact degree and nature of such cost 
reductions would be predicated on the payer having a per diem reimbursement 
structure with the treating facility so that a reduction in LOS has a corresponding 
reduction in dollars incurred. 
From the view of the health care provider (institution or practitioner) a 
reduction in ALaS may have no impact in the total costs incurred for the NICU 
experience. Providers often suggest that true costs of care are, in fact, non-
linear and greatest in the first few days or weeks of care. Kaufman and Shepard 
(1982) first reported this non-linear and inverse relationship between a neonatal 
intensive care patient's day of life and the quantity of hospital resources required 
to provide their care. Further research is required to determine if this 
phenomenon continues to exist now some twenty years later. 
Limitations 
Several limitations of this study should be noted. First, several factors affect 
the incidence of low birth weight infants, their outcomes, and the resulting length 
of stay_ These factors, the measurement of which is challenging, include 
individual characteristics such as ethnicity, gestational age, intrauterine growth 
retardation, maternal smoking, and education (Bronstein, Carpilouto, Carlo, 
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Haywood, & Goldenberg, 1995; Demisse et aI., 1997; Lightwood, Phibbs, & 
Glantz, 1999). In addition, other differences that affect infant outcomes but are 
not reliably measured include poverty, local interpretations of the level of 
intensive care provided, intensive care unit volume and practice style, and place 
of delivery (Bird & Bauman, 1998; Crosse, Alder, Ostbye, & Campbell, 1997; 
Kirby, 1996; Phibbs, Bronstein et aI., 1996; Powell, Holt, Hickok, Easterling, & 
Connell, 1995; Yeast, Poskin, Stockbauer, & Shaffer, 1998). 
This study effort was limited by the nature of the research datasets used in 
this analysis. In order to control for facility coding and billing practices of 
providers within its database, the MillimanUSA dataset excludes neonatal deaths 
and infants discharged from the NICU within 5 days of admission, as such short 
stays are not representative of the general neonatal intensive care population. 
The ParadigmHealth sample size, while greater than 500 cases, was 
relatively small when sorted by the various APR-DRG categories (132 categories 
in all). In addition to the twelve APR-DRG mean differences that were 
considered inconclusive due to relatively small sample size (n < 25), additional 
mean differences may be relevant but cannot be shown to be significant due to 
the limitations of the ParadigmHealth cases within those APR-DRGs. 
In addition, while nationally recognized as the best severity adjustment 
parameter currently available in neonatal care, the APR-DRG weighted score for 
a patient may be influenced by human error in the classification and recording of 
secondary diagnosis and procedure codes. 
This research assumes the presence of nationally accepted evidence-
based protocols for the care of high-risk infants in neonatal intensive care. The 
real world variability in neonatal intensive care practices (and their resultant 
outcomes) across facilities, regions and the Nation present a limitation and 
challenge to this research effort. 
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Finally, use of the MillimanUSA dataset and the California OSHPD dataset 
as a convenience sample for this study, while robust, may not represent the 
actual practice patterns of the nation's NICUs. As such, conclusions drawn for 
this study may have limited applicability or clinical relevance to nation-wide 
neonatal intensive care practice. 
Opportunities for Future Research 
This study has provided preliminary but inconclusive information about the 
effect of physician collaboration in providing medical services for the neonatal 
population. A follow-up study involving additional ParadigmHealth cases could 
strengthen the case for SCM. A future study could further quantify the utility of 
SCM by determining the variance in patient emergency room visits and re-
admission rates following NICU discharge for each of these datasets. In 
addition, future study is warranted to determine the relationship, if any, between 
a reduction in NICU length of stay and a corresponding reduction in provider 
defined or payer defined costs. 
An additional research opportunity exists to determine the economic 
impact to both the provider and purchaser of NICU services by/realizing a 
112 
reduction in NICU lengths of stay. Further study might contrast the application of 
SCM to small, community NICUs to those in larger, tertiary (or teaching) 
institutions. 
Additional research specifically focused on the differences in the range of 
LOS identified in this study between the ParadigmHealth dataset and both 
comparison samples may reveal opportunities to use predictive modeling as a 
basis for further collaboration between providers and payers for this highly 
complex and costly population. 
Summary 
It has long been recognized in the public policy domain that a crisis 
situation is usually necessary, but not sufficient, to ensure significant policy 
action (Schwartz, 1998). Brown suggested two other political conditions 
prerequisite for action to occur: (1) A "call to arms" by policy makers who are 
persuaded that the problem is urgent, and (2) Consensus on a defined, easily 
understood strategic model to address the problem (Gardner, 1999). 
Over the past decade, the U.S. health care delivery system has been 
undergoing an almost perpetual process of reconfiguring various provider 
arrangements and financing structures. Such fundamental, ongoing 
organizational changes have affected virtually all populations. The crisis 
situation derives from a growing concern about the ability of constantly evolving 
organizational models of care delivery to preserve health care access and quality 
while containing costs, especially for vulnerable populations. ~i 
Nevertheless, there is a consensus among vested parties that the 
objectives of a health care system should include the following: 
1. To manage health care costs, 
2. To improve access to care, 
3. To maintain or improve quality of care, and 
4. To establish equitable priorities for allocating finite health care 
resources (Gardner, 1999). 
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Yet the saga of neonatology is emblematic of how a market-driven health 
care system with inadequate public planning can produce too much of a good 
thing - the overgrowth of this specialty likely comes at the expense of under-
investment in less glamorous primary care and public health services that avert 
poor birth outcomes (Grumbach, 2002). NICUs are economically successful 
because they are medically successful (Lantos, 2001). NICUs are profit-making 
centers for hospitals, commanding high payments from private and public 
insurance plans. One of the few investor-owned physician groups to remain 
financially successful is in the business of providing neonatal services through 
more than 600 employed neonatologists in over 190 NICUs across the U.S. and 
earned more than $68.8 million in net profits for investors in 2002 (Investors, 
2003). 
While not conclusive, this study argues that a SCM approach to the 
management of NICU patients has a compelling potential to satisfy these core 
objectives. The foundation of the SCM approach has the capability to transform 
the process of NICU care through evidence-based decision-making, by iteratively 
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examining relationships between process and outcome, eliminating inappropriate 
services, and enhancing both the efficiency and the outcome of the care that is 
delivered (Cope, Bryant et aI., 2001). SCM has the potential to resolve three of 
the most salient concerns about the effectiveness of managed care: lack of 
scientific evidence by which to base decisions about alternative clinical 
pathways; appropriateness and timelines of services rendered; and fiscal 
accountability, particularly germane to catastrophic injuries and conditions 
(McLean et aI., 2002). 
While many attempts have been made to restrain health care costs 
rationally while maintaining quality of care, skepticism still abounds about the 
ability of traditional managed care models to meet these objectives. More and 
more, if market considerations displace the professional authority of physicians 
(Silver, 1997), there will be greater need for rigorously collected data on costs 
and effectiveness by which to base, and evaluate, clinical decisions and selection 
of providers. 
The history of public health legislation indicates that public policy will 
respond when the preponderance of evidence suggests a clear and pressing 
need and a clearly defined solution. The literature review (chapter 2) documents 
that a clear and pressing need has been established and the findings of this 
study suggest that systematic care management (SCM) may prove to be a 
solution (with additional case volume). Systematic care management is a model 
worthy of review by insurers, providers, payers and consumers alike. It is also an 
area for further study and research by the academic community. 
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Appendix A 
Definition of Terms 
ADC - Average daily census (patient volume/day). 
Assessment - An evaluation and data gathering performed by the 
ParadigmHealth team. Demographic information; a description of the patient's 
history of injury or disability, current medical, functional and psychosocial status; 
and pre-morbid information is collected and analyzed. 
APR-DRG Classification System - a patient classification system that was 
developed by 3M Health Information Systems and modeled after the All Patient 
DRG system. This classification system uses hospital patient discharge data and 
computer-based logic to assign patients to severity of illness and risk of mortality 
classes so they can be accurately compared in terms of length of stay, resource 
consumption, and outcomes. 
Birth-weight Classifications - There is no universal agreement on birth-
weight classification. The commonly accepted definitions follow: 
Macrosomia - 4000 grams or more. 
Normal Birth Weight - 2500 - 3999 grams. 
Low Birth Weight - Less than 2500 grams. 
Very Low Birth Weight - Less than 1500 grams. 
Extremely Low Birth Weight - Less than 1000 grams. 
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Clinical Practice Guidelines (CPGs) - Systematically developed 
statements to assist practitioner and patient decisions about appropriate health 
care for specific clinical circumstances (Field & Lohr, 1990; Kurec, 1996). 
Diagnostic Related Groups (DRGs) - Classification system developed at 
Yale University using 383 major diagnostic categories based on the ICD-9 codes. 
A system for determining case mix, used for payment under Medicare's PPS and 
by some other payers. The DRG system classifies patients into groups based on 
the principal diagnosis, type of surgical procedure, presence or absence of 
significant co-morbidities or complications, and other relevant criteria. DRGs are 
intended to categorize patients into groups that are clinically meaningful and 
homogeneous with respect to resource use. Medicare's PPS currently uses 490 
mutually exclusive DRGs, each of which is assigned a relative weight that 
compares its costliness to the average for all DRGs (3M Health Information 
Systems, 1995). 
Disease Management - The integrated monitoring of a patient, particularly 
with a chronic illness, to focus on prevention of recurrence, improved quality of 
life, and cost-effective care. Also refers to the systematic study of a diagnosiS or 
intervention to focus on the outcomes of a population, rather than an individual 
patient. 
ECMO - Extracorporeal membrane oxygenation (ECMO) is a life support 
technique used for profound cardiorespiratory failure in infants who fail to 
respond to conventional therapy. The infant's venous blood is pumped through a 
membrane oxygenator (artificial lung) whereby oxygen is added and carbon 
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dioxide is removed. The blood is then pumped back into the patient's venous or 
arterial circulation. The procedure allows the lungs to rest and averts continuous 
high-pressure mechanical ventilation in severe respiratory failure (Kanto, 1994). 
Evidence-Based Medicine (EBM) - The conscientious, explicit and 
judicious use of current best evidence in making decisions about the care of 
individual patients (Field & Lohr, 1990; Sackett & Guyatt, 1992). 
Gestational Age - The age of the infant based upon the date of the 
mother's last menstrual period. Gestational age is classified as (a) preterm -
Less than 37 weeks, (b) term - 37 to 41 and 6/7 weeks, and (c) postterm - 42 
weeks or more. 
Infant - An infant is a live born fetus from time of birth through the 
completion of one year of age (Committee on Perinatal Health, 1976). 
Intermediate Care Nursery (ICN) - An ICN is a specialized nursery that 
provides skilled care for premature infants and newborns. 
International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) - A diagnosis and procedure classification system 
designed to facilitate the collection of uniform and comparable health information. 
ICD-9-CM was issued in 1979 and is updated periodically. This system is used 
to group patients into DRGs. 
Length of Stay (LOS) - Length of stay in the NICU is defined as the date 
of discharge - the date of admission. 
Levell Nursery - No NICU, caring only for healthy infants. 
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Level II Nursery - An Intermediate NICU, caring for moderately sick 
infants. Most often with an average daily census of < 10 -13 patients. 
Level 11(+) Nursery - Community NICUs providing many but not all 
services of a level III regional tertiary care NICU facility. Small units have an 
average daily census <15 patients while large units have an average daily 
census of 15 or greater patients. 
Level III Nursery - Regional or tertiary care NICU, providing a full range of 
NICU services, including pediatric subspecialty consultations and surgery. These 
units typically have an average daily census of 15 or greater. 
Managed Care - A system that manages or controls what it spends on 
health care by closely monitoring how physicians and other medical 
professionals treat patients. Various techniques for keeping costs down include 
limiting coverage to care provided by specially selected doctors and hospitals 
and requiring preauthorization for hospital care and other services. Managed 
care describes a collection of health plan activities designed to reduce the high 
levels of utilization and spending that accompany unfettered fee-for-service 
health care (Baker & Phibbs, 2002). 
Medical Standards of Care - Known practices that are medically 
necessary and services that any health care practitioner under any circumstance 
would be required to render (Havighurst, Hutt, McNeil, & Miller, 2001). 
Neonate - an infant born at less than 38 weeks gestation, or an infant 
greater than 38 weeks gestation that requires hospitalization in a NICU. 
137 
Neonatal Intensive Care Unit (NICU) - The NICU is a specialized nursery 
that provides highly skilled care for premature or sick newborns. For this study, 
Neonatal Intensive Care Unit (NICU) is defined as a specialized nursery that 
provides highly skilled services for very low birthweight (VLBW) and low 
birthweight (LBW), and medically fragile newborn infants. 
Prospective Payment System (PPS) - Medicare's acute care payment 
method for inpatient care. Prospective payment rates are set at a level intended 
to cover operating costs for treating a typical inpatient in a given diagnosis-
related group. Payments for each hospital are adjusted for differences in area 
wages, teaching activity, care to the poor, and other factors. Hospitals may also 
receive additional payments to cover extra costs associated with atypical patients 
(outliers) in each DRG. 
Utilization Review (UR) - The review of services delivered by a health 
care provider to evaluate appropriateness, necessity, and quality of the 
prescribed services. The review can be performed on a prospective, concurrent, 
or retrospective basis. 
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Appendix 8 
Systematic Care Management Process 
ParadigmHealth's management process has the capability to scientifically refine 
care processes over time by repeatedly examining the relationships between 
process and outcome, eliminating inappropriate services, and enhancing both the 
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Definition of Tier Groups and APR-DRG Assignments 
Each tier is based upon the clinical resources required to ensure high quality and 
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639-1,2,3 638-1,2,3 637-1,2,3 
635-1,2,3 634-1,2,3 633-1,2,3 
631-1,2,3 630-1,2,3 626-1,2,3 
624-1,2,3 623-1,2,3 622-1,2,3 
620-1,2,3 
613-1,2,3 612-1,2,3 611-1,2,3 
602-1,2 601-1,2 600-1,2 
592-1 ,2,3,4 591-1,2,3,4 
639-4 638-4 637-4 
634-4 633-4 632-4 
626-4 625-4 624-4 
621-4 620-4 614-4 
611-4 610-4 







Expected Birth Weights 
The (5dh Percentile) at 24 - 28 Weeks' Gestation (Battaglia, 1967) 
Gestational Age Birth Weight (grams) 
24 
26 
28 
30 
32 
34 
36 
38 
700 
900 
1100 
1350 
1650 
2100 
2600 
3000 
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